{
  "name" : "zero.sci-hub.se_6112_a24ea559128fc0a3b755e41d3a634e63_mahmoudi2016.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Emerging understanding of the protein corona at the nano-bio interfaces",
    "authors" : [ "orteza Mahmoudi", "Nicolas Bertrand", "Harshal Zope", "Omid C. Farokhzad" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "N R\nE i\nM a b c d\na\nA R R A A\nK N P T T\nC\nI\no\no U\no\nh 1\nContents lists available at ScienceDirect\nNano Today\njourna l homepage: www.e lsev ier .com/ locate /nanotoday\neview\nmerging understanding of the protein corona at the nano-bio nterfaces\norteza Mahmoudi a,b,∗, Nicolas Bertrand c, Harshal Zope a, Omid C. Farokhzad a,d,∗\nCenter for Nanomedicine, Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, United States Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Faculty of Pharmacy, CHU de Quebec Research Center, Université Laval, Québec, G1 V 4G2, Canada King Abdulaziz University, Jeddah 21589, Saudi Arabia\nr t i c l e i n f o\nrticle history: eceived 4 August 2016 eceived in revised form 3 September 2016 ccepted 17 October 2016\na b s t r a c t\nUpon entering the physiological environment, nanoparticles (NPs) are immediately surrounded by a complex and tightly bound layer of biomolecules, or ‘(hard) protein corona’. The corona controls NP fate in vivo and becomes the interface with cells. One of nanomedicine’s central goals is to make NPs capable of active targeting in both imaging and therapy. If the NP is not designed correctly, the resulting corona\nvailable online xxx\neywords: anoparticles rotein corona argeting herapeutic efficacy\ncan cause mistargeting and aberrant biodistribution, unanticipated toxicity, and low therapeutic efficacy. Here we present groundbreaking concepts about nanobio interactions and discuss approaches to bypass protein corona issues and thus enhance the efficacy of NPs.\n© 2016 Elsevier Ltd. All rights reserved.\nontents\nIntroduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 Protein corona affects active targeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 Protein corona affects drug release . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 Controlling protein-corona structure for high-Yield active targeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 Surface functionality directs protein corona profile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 Pre-coating with other proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00\nCorona-free interfaces for high-yield targeting and delivery applications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .00 Personalized protein corona: new challenge at the nanobio interface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 Conclusions and future perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 Conflict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00\nAcknowledgement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00\nfewer have reached clinical practice. Recent reports revealed that\nPlease cite this article in press as: M. Mahmoudi, et al., Emerging unde Today (2016), http://dx.doi.org/10.1016/j.nantod.2016.10.005\nntroduction\nDespite advances in nanoparticle (NP) drug carriers and numerus publications, few NPs have made it to clinical trials, and even\n∗ Corresponding authors at:Center for Nanomedicine, Department of Anesthesilogy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, nited States.\nE-mail addresses: mmahmoudi@bwh.harvard.edu (M. Mahmoudi), farokhzad@bwh.harvard.edu (O.C. Farokhzad).\nttp://dx.doi.org/10.1016/j.nantod.2016.10.005 748-0132/© 2016 Elsevier Ltd. All rights reserved.\nthe wide gap between bench discoveries and clinical translation is, at least in large part, due to our incomplete understanding of the interactions between NPs and living organisms [1–6].\nOnce in the body, the surface of NPs is rapidly covered by proteins to form a dynamic corona (the so-called “soft” corona) [6]; after a few minutes, NPs become surrounded by a long-\nrstanding of the protein corona at the nano-bio interfaces, Nano\nlived (“hard”) corona layer, which remains strongly adsorbed to their surfaces [3,7]. The affinity of the proteins for the surface of NPs is governed by a variety of complementary physical forces: Van der Waals interactions (VDW), hydrogen bonding (H-\nF ce, (A) (\nb [ v t s b t o p b [ c t o m i c a a h e t b t w\n( w f [ s h a s\nig. 1. Schematic representation of biochemical interactions at the NanoBio interfa D) Hydrophobic (depicted as green) interaction.\nond), as well as electrostatic and hydrophobic interactions (Fig. 1) 8]. The relative importance of each of these forces depends on arious parameters, including the size and the chemical properies of the nanoparticle surface [9]. VDW forces are weak and hort-range electrostatic attractions between dipoles. H-bonding etween uncharged hydrophilic parts of the proteins (e.g., serine, hreonine, asparagine and glutamine residues) and polar residues n the surface of the NP (e.g., hydroxyl on oxidized metals) is also ossible. These interactions are individually stronger than VDW, ut usually less abundant in aqueous physiological environments 8]. Materials that exhibit charged surface groups (e.g., amines or arboxylic acid) can also form cooperative electrostatic interacions with ionized proteins. These happen despite the presence f various ions in the biological fluids, because polyionic macroolecules can often better neutralize surface charges. Electrostatic nteractions are believed to play a pivotal role in bringing proteins lose to the surface of nanoparticles. Hydrophobic interactions can lso occur on the surface of certain materials (e.g. polystyrene nd polyesters). In proteins with secondary and tertiary structures, ydrophobic residues (e.g., alanine, valine, phenylalanine and othrs) often form rigid dehydrated regions, buried inside the core o minimize contacts with surrounding water. When weak forces ring these apolar regions in the vicinity of hydrophobic surfaces, he protein conformation can change and form strong interactions ith the nanoparticle [10].\nThe effect of any NP on biological components such as cells and vice versa) strongly depends on the corona composition, hich in turn depends on the physicochemical properties (e.g., surace chemistry, size, shape, and stabilizer density) of the particle 2,10,11]. Therefore, while it is now possible to synthesize NPs with pecific physicochemical properties, we have much to learn about\nPlease cite this article in press as: M. Mahmoudi, et al., Emerging unde Today (2016), http://dx.doi.org/10.1016/j.nantod.2016.10.005\now the formation of the protein corona affects the hypothetic therpeutic efficacy of NPs and can induce unwanted mistargeting and ide effects [12,13].\nVan der Waals interaction, (B) Electrostatic interaction, (C) Hydrogen bonding and\nCurrent efforts in nanomedicine are centered on novel approaches to control the biological identity of NPs, optimizing in vivo therapeutic efficacy, and accelerating clinical transition [14–20]. Recent findings reveal an urgent need for a deeper understanding of the biological identity of NPs, facilitating more predictable nanotherapeutic design and personalized nanomedicine [16,21–26]. In this review we will discuss recent findings relevant to diminishing the negative effects of the protein corona on active targeting and therapeutic efficacy of NPs.\nProtein corona affects active targeting\nSurface functionalization of NPs with specific targeting ligands (e.g., aptamers, antibodies, and affibodies) is used for selective delivery of therapeutic biomolecules to desired anatomical sites. Targeted NPs have been shown to work perfectly in finding their target cells in vitro —if serum-free or low-protein medium (e.g., 10% for cell culture) is used [27]. However, in vivo targeting efficacy was much poorer [28,29]. In 2011, we posited that the formation of the protein corona is behind the wide disparity between in vitro and in vivo results, i.e., it may limit the accessibility of the targeting ligands to cell receptors [30]. In 2013, further experiments revealed that the protein corona can significantly cover the targeting ligand at the surface of NPs and cause mistargeting [31,32].\nAs a model targeting reaction, Mirshafiee et al. [32] used copperfree click reaction between NPs and silicon substrates (Fig. 2(A)). The silica NPs and silicon substrates were functionalized with bicyclononyne (BCN; a strained cycloalkyne) and azide groups, respectively. The targeting efficacy of the NPs toward silicon substrates was probed in the presence and absence of protein corona using a variety of techniques including fluorescence microscopy\nrstanding of the protein corona at the nano-bio interfaces, Nano\nand scanning electron microscopy (SEM). It is noteworthy that protein coronas were formed in the presence of 10% (to mimic in vitro conditions) and 100% (to mimic in vivo conditions) serum. Both fluorescence microscopy and SEM images confirmed that pro-\nFig. 2. (A) Schematic illustration of the model targeting reaction based on copper-free click reaction between the bicyclononyne groups on the NPs and the azides on the modified silicon substrate. (B) Cartoon showing how the protein corona can blind the targeting species on the surface of NPs. (C) Scanning electron microscopy images of the attached NPs to the surface of modified silicon substrates, with azide groups, in the absence (a and b) and presence of protein corona with serum concentration of (c) 10% and (d) 100%. (D) Fluorescence microscopy images of 5 mm by 5 mm silicon substrates after incubation with NPs demonstrating (a) negligible non-specific binding and (b) numerous specific binding of pristine NPs to the azide-free and the azide-functionalized substrates, respectively. (c and d) Presence of protein corona, after incubation o eir att S conju\nS f chem\nt ( r b T o t\nr t a t\nf particles with (c) 10% or (d) 100%, on the surface of NPs significantly reduced th chematics showing (E) the recognition and (F) loss of targeting for transferrin (Tf)-\nource: Printed with permission from Nature publishing group and Royal society o\nein corona substantially reduced the targeting efficacy of the NPs Fig. 2(B)–(D)). Quantitative analysis of fluorescence microscopy esults revealed that the targeting efficiencies of NPs were reduced y 94% and 99% by in vitro and in vivo conditions, respectively. his suggests that, in this experimental setting, very small amounts f proteins can prevent nanoparticles from interacting with their arget.\nBeside simulating the targeting reactions, Salvati et al. [31]\nPlease cite this article in press as: M. Mahmoudi, et al., Emerging unde Today (2016), http://dx.doi.org/10.1016/j.nantod.2016.10.005\nevealed the role of the protein-shielding effect in NP-cell interacions. They synthesized silica NPs functionalized with transferrin nd observed their uptake by A549 lung epithelial cells through heir specific interactions with transferrin receptors in the absence\nachment to the azide-functionalized substrates. Arrows designate individual NPs. gated NPs in the absence and presence of protein corona, respectively.\nistry. [31,32].\nof any protein corona (Fig. 2(E)). In the presence of a protein corona, however, they found that the corona covered the transferrin protein at the surface of NPs, substantially reducing the receptor-mediated uptake of NPs by A549 cells (Fig. 2(F)). These findings clearly implicate the protein corona in the dramatic disparity between in vitro and in vivo outcomes of NP targeting efficacy.\nAlthough they clearly highlight how the adsorption of proteins can alter the affinity of NPs for their intended targets, these\nrstanding of the protein corona at the nano-bio interfaces, Nano\nexperiments were conducted on material without intrinsic steric protection. The importance of protecting the NP surface to maintain specificity will be discussed in the section titled “Corona-Free Interfaces for High-Yield Targeting and Delivery Applications.”\nFig. 3. (A) Cartoon showing the inhibiting role of protein corona on drug release. (B) Release profile of tamoxifen from various coated SPIONs (non-crosslinked and crosslinked PEGF) in the absence and presence of FBS (10% and 100%) over 30 h. (C) Paclitaxel release profile from Abraxane in the absence and presence of FBS (with various concentrations; i ofile o o\nS\nP\nw a p t w e r r t n t h c\np s [ e t f w p e s m f s 1 p w f s f\n.e., 10% and 100%) in both in situ and after removal of excess proteins. (D) Release pr ver 80 h.\nource: Printed with permission from Elsevier publishing group [40].\nrotein corona affects drug release\nA “magic bullet” to deliver drugs selectively to diseased cells as proposed more than 100 years ago [33]. However, though\nsingle cure is generally unrealistic, selective drug delivery is articularly appealing in cancer therapy, where significant sysemic toxicity limits the therapeutic index. Recent decades have itnessed a plethora of sophisticated drug-delivery systems to nhance safety and efficacy, including crosslinkable and stimuliesponsive targeted polymeric nanocarriers [34–36]. Despite much esearch designed to understand the controlled-release profiles of herapeutic agents in vitro, the in vivo drug release profiles of these anocarriers remains poorly understood. This is mainly because he critical role of the protein corona layer on the release profile as been overlooked, and the profiles were probed with very low oncentrations (∼10% of serum) or even absence of proteins.\nIt is widely accepted that upon intravenous administration, olymeric micelles circulate systemically and deliver their encapulated payload after uptake by target cells. Chen and coworkers 37,38] explored further, with astonishing results. The authors mployed a Förster resonance energy transfer (FRET) approach o gain a better understanding of the release of cargo molecules rom polymeric micelles. DiIC18(3) and DiOC18(3), a FRET pair,\nas loaded into the monomethoxy poly(ethylene glycol)-blockoly(D,L-lactic acid) micelles [37]. The authors found that FRET fficiency decreased even before intracellular uptake by the cells, uggesting that the micelles are unstable in the protein and embrane environment, which in turn affects their capacity or intracellular drug delivery. The same authors later demontrated that FRET efficiency was significantly diminished within 5 min after intravenous injection when the same FRET pair in oly(ethylene glycol)-poly(d,l-lactic acid) (PEG-PDLLA) micelles ere used [38], suggesting that DiIC18 and DiOC18 rapidly escaped\nPlease cite this article in press as: M. Mahmoudi, et al., Emerging unde Today (2016), http://dx.doi.org/10.1016/j.nantod.2016.10.005\nrom the systemically circulating micelles. Furthermore, it was hown that the - and -globulins were major contributors to the ast release of encapsulated cargo in vivo.\nf 4-nitroanisole from nanocapsules, in the presence and absence of protein corona,\nCifuentes-Rius et al. [39] revealed that the protein corona can substantially change the release profile of the DNA payloads of various nanoparticles including gold nanorods, nanobones, and carbon nanotubes. They also found that the corona composition can be tuned to adjust the payload release profile. To acheive better underestanding on in vivo release profile, Behzadi et al. [40] probed the effect of protein corona on release profiles of various nanocarriers including polyethyleneglycol-co-fumarate (PEGF)-coated superparamagnetic iron oxide nanoparticles (SPIONs), poly(methyl methacrylate) polymeric nanocapsules, and commercialized Abraxane® nanocarriers (i.e., the albumin-bound drug paclitaxel). Monitoring of the drug-release profiles of these selected nanocarriers revealed that the protein corona substantialy reduced the burst effect of both protein-drug conjugates (Abraxane®) and drug-loaded PEGF-coated SPIONs (Fig. 3). Conversely, the protein corona layer only slightly changed the release profile of polymeric nanocapsules, mainly due to the fact that capsule’s shell is the limiting step for drug diffusion, i.e.,: 1) the hard corona shell is much thinner than the nanocapsule shell (∼10 nm vs. ∼32 nm) and 2) the nanocapsule shell is much harder (mainly because of its high glass transition temperature, ∼100 ◦C) than the corona shell. Therefore, though the protein corona might have negligible effects on drug release from all nanocapsules with monolithic membrane shells, it may play a critical role in the release profiles of payloads from porous nanocapsules.\nAccording to these findings, the protein corona plays a crucial role in controlling the buffer effect of carriers on their drug payloads, which is important in reducing the side effects of anti-cancer drugs and modulating [if you mean that it increases their efficacy, you could say that directly; ‘modulating’ means a smaller effect and is neither positive nor negative] their therapeutic efficacy in vivo. In addition, these findings suggest that the currently available data on the release profile of various nanocarriers might not be valid\nrstanding of the protein corona at the nano-bio interfaces, Nano\nin vivo, and those results should be reinterpreted considering the role of the protein corona.\nF he un p\nS\nC t\nt n t o p w w m t w m\nS\nc F a w r s t r N [ N w a t c p g\nm m w t a p c u a\nig. 5. The normalized abundance of identified proteins in the protein corona of t rotein classification.\nource: Printed with permission from Elsevier publishing group [42].\nontrolling protein-corona structure for high-Yield active argeting\nTo evade the shielding effect of the protein corona (covering he targeting ligand) and create efficient in vivo active targeted anoparticles (NPs), several strategies have been developed to conrol the composition of the protein corona in favor of targeting. In ne strategy, the surface of NPs is engineered to recruit targeting roteins from the in vivo environment (e.g., human plasma). In other ords, the protein corona composition is intentionally enriched ith proteins to enhance targeting efficacy. There are two possible ethods to achieve these goals. One is controlling the surface funcionality [41] of NPs and the other is pre-coating the surface of NPs ith specific proteins [42] to recruit similar proteins from plasma ainly via protein–protein interactions.\nurface functionality directs protein corona profile\nThe surface functionality of NPs controls the protein corona omposition and dictates interactions with target cells [41,43–45]. or example, it has been demonstrated that surface modifications of lkyne-terminated thermally hydrocarbonized porous silicon NPs ith dextran reduces the percentage of immune proteins (e.g., fibinogen and immunoglobulin G) in the protein corona [46]. This ignificantly lessens the chance of recognition by the immune sysem and the NPs’ consequent clearance by phagocytosis. We have ecently shown that modulating the surface functionalities of gold Ps substantially changes the composition of the protein corona 25]. More specifically, using a series of engineered cationic gold Ps (Fig. 4(A)), we found that the formation of the protein corona as substantially dependent on hydrophobicity as well as the rrangement of chemical motifs on the NP surface. These NPs were aken up by macrophages, mainly through recognition of specific omplement proteins in the corona. Thus, specific protein-induced hagocytosis by macrophages can be considered a simplified tareting model of corona-mediated NP uptake by a desired cell type.\nTo determine how different types of proteins contribute to acrophage recognition, we examined the correlation between acrophage uptake pattern and corona composition of gold NPs ith various surface functionalities. We found that proteins from he complement, apolipoprotein, and coagulation categories had substantial influence on macrophage uptake (Fig. 4(B)). As\nPlease cite this article in press as: M. Mahmoudi, et al., Emerging unde Today (2016), http://dx.doi.org/10.1016/j.nantod.2016.10.005\nredicted, the presence of complement proteins in the corona omposition accelerated macrophage uptake, while immunogloblins reduced uptake. Complement component 4 binding protein lpha (C4BPA) and immunoglobulin lambda constant 2 (IGLC2) had\ncoated (UC) NPs and the NPs pre-coated with gamma-globulins (GG) according to\nthe highest positive and negative correlation coefficient (r) with macrophage uptake, respectively (Fig. 4(C)). Interestingly, one of the main roles of C4BPA is to label apoptotic/necrotic cells for immune system clearance, which explains why positive r with macrophage uptake was observed for NPs with C4BPA-rich corona composition [47,48]. An analysis of the proportion of the C4BPA and IGLC2 proteins in the corona composition of various NPs according to their uptake behavior suggests that those with higher C4BPA (i.e., hydrophilic NPs: NP1 and NP2) had high uptake, while NPs with low C4BPA (i.e., hydrophobic NPs) were subject to lower macrophage uptake. This demonstrates that modulating NP surface hydrophobicity is a straightforward way to reduce macrophage recognition (Fig. 4(D)). Compared with hydrophobic NPs, hydrophilic NPs demonstrated lower uptake by macrophages, mainly due to the higher association of the IGLC2 proteins in their corona composition (Fig. 4(E)). In addition to the predetermined proteins, Schöttle et al. [49] demonstrated that a substantial proportion of clustrin protein in the corona composition can significantly reduce a nanoparticle’s uptake by macrophages. Thus we propose that the surface functionality of NPs plays a crucial role in regulating protein corona composition and, therefore, in targeting by macrophages. We have recently shown that tumor-associated macrophages play a critical role in the efficacy of NPs by acting as a slow-release reservoir of payload drugs into the tumor microenvironment [50]. Therefore, tuning the surface functionality of NPs could be a valuable means to control the tumor-associated macrophage recognition of NPs, and thereby their total efficacy and tumor distribution.\nPre-coating with other proteins\nAnother method of recruiting targeting proteins into the protein corona is to pre-coat NPs with specific proteins to attract desired proteins for the corona, mainly through protein–protein interactions [51]. Although there are extensive reports on the covalent and non-covalent attachment of proteins to the surface of NPs to enhance targeting efficacy (e.g., using ApoA-i and ApoB-100 to cross the blood-brain barrier and target brain tissue [52]), the role of ultimate in vivo identity of NPs in targeting remains unknown. To utilize the power of protein–protein interactions to control the ultimate biological identity of NPs, Mirshafiee and co-workers [42] used a pre-coating strategy to direct the formation of a protein corona that is targeted by\nrstanding of the protein corona at the nano-bio interfaces, Nano\nimmune cells (e.g., RAW 264.7 macrophages). They specifically intended to attract more opsonin-based proteins onto the surface of silica NPs to enhance opsonin-induced phagocytosis by macrophages. They chemically conjugated gamma-globulins (g-\nmmuno-dot blot assays showing the amount of the exposed immunoglobulins at G-NPs (3) compared to the corona-UC-NPs (1), corona-GG-NPs (2), and GG-NPs th\nrfaces of various NPs. Higher amounts of immunoglobulins were detected on the been exposed to medium consisting of DMEM/serum (9/1 vol/vol) (4).\nFig. 7. Schematic showing unfolding and the epitopes buried inside targeting proteins (e.g., immunoglobulins, complement factors, and coagulation proteins) for Fc receptors of macrophages. Although corona composition is enriched with opsonins, the unavailability of these proteins to cell receptors inhibits a significant increase in NP uptake by immune cells.\nSource: Printed with permission from American Chemical Society publishing group [56].\nFig. 8. Schematic representation of transferrin-coated polystyrene particles incubated with similar concentrations of immunogold-labeled monoclonal (mTf) (A), polyclonal (pTf) (B) and their corresponding TEM images (C) and (D) respectively. (E) Differential Centrifugal Sedimentation (DCS) distributions, in apparent diameter, for increasing c les fo i es in\nS\nc w\nn F h u\noncentrations of double-titration (mTf + pTf) transferrin-coated polystyrene partic n grey followed by transferrin-coated polystyrene in orange, then successive chang\nource: Printed with permission from Nature publishing group [23].\norona composition of both uncoated (UC) NPs and NPs pre-coated ith gamma-globulins (GG) (see Fig. 5).\nThe protein corona created through this approach should sigificantly enhance the interactions of these particles with the\nPlease cite this article in press as: M. Mahmoudi, et al., Emerging unde Today (2016), http://dx.doi.org/10.1016/j.nantod.2016.10.005\nc receptor on certain cells (e.g., natural killer cells, neutrophils, uman platelets, and macrophages [53,54]). Mirshafiee et al. [55] sed macrophage RAW 264.7 cells to track the targeting capa-\nllowed by monoclonal (mTf) and polyclonal (pTf) immunogold labels. Polystyrene color referring to incremental changes in label concentration.\nbility of the immunoglobulin-decorated protein corona. However, the engineered protein corona (opsonin-rich) did not substantially increase NP uptake by macrophages (Fig. 6(A)–(D)). More specifically, both flow cytometry and confocal microscopy con-\nrstanding of the protein corona at the nano-bio interfaces, Nano\nfirmed that the GG-NPs had significantly higher uptake compared than either corona-UC-NPs or corona-GG-NPs. Theoretically, the immunoglobulin-rich protein corona should act as a ligand to\nFig. 9. (A) Schematic illustration of surface modification of silicon substrates with streptavidin. (B) SDS-PAGE gels showing the hard-corona profiles of the biotin-conjugated silica NPs (Bio-NPs) and cysteine-biotin-conjugated silica NPs (Cys-Bio-NPs) after incubation with different human plasma concentrations (10–50%) and protein adsorbed on the surface of modified wafers in 50% plasma after two washes with PBS. (D-E) Fluorescence microscopy images of the modified silicon substrates after incubation with various NPs including pristine Cys-Bio-NPs (cysteine-biotin-conjugated silica NPs), Cys-NPs, and Bio-NPs. Fluorescence Images of the attached (D) pristine Cys-Bio-NPs to the substrate showing their strong binding to streptavidin, (E) pristine Cys-NPs attached to the streptavidin substrate showing no specific interactions, and (F) pristine Bio-NPs d nume ( g in a\nS [68].\nb i i b p t o c p\no a a c i f a n i o\nemonstrating strong binding to the substrate. Fluorescence images demonstrating H) 50%, and (I) 100% human plasma, showing the strong role of zwitterionic coatin\nource: Printed with permission from American Chemical Society publishing group\nind to macrophages’ receptors and provoke phagocytosis. Further mmunolabeling experiments using western blotting revealed that mmunoglobulins failed to bind to their target cell surface receptors ecause their active sites were not exposed to the outer layer of the rotein corona (Fig. 6(E)). Caracciolo et al. [56] also demonstrated hat particles whose corona composition was highly enriched in psonins could not bind to macrophage receptors and elicit phagoytosis, mainly due to the unfolding or unavailability of opsonin roteins in the outer corona layer (see Fig. 7).\nA thorough structural understanding of the proteins adsorbed n the surface of NPs is important in the development of therpeutic nano-biomaterials. In a quite interesting study, Kelly nd co-workers [23] performed epitope mapping on transferrinoated polystyrene NPs 220 nm in size. The authors used an mmunogold-labeled monoclonal antibody (mTf) (Pro142–Pro145) or an epitope proximal to the transferrin receptor binding region\nPlease cite this article in press as: M. Mahmoudi, et al., Emerging unde Today (2016), http://dx.doi.org/10.1016/j.nantod.2016.10.005\nnd a immunogold-labeled polyclonal antibody (pTf) to recogize multiple epitopes simultaneously [57,58]. The results were nstrumental in understanding the transferrin corona organization n the surface of the nanoparticle. The spatial organization and\nrous conjugations of the corona-coated Cys-Bio-NPs after incubation with (G) 10%, voiding the mis-targeting effects of the protein corona.\nconformation governed the binding efficiency for this monoclonal antibody. Conversely, the polyclonal antibody would recognize the vast majority of the epitopes available on the surface for binding. The authors found that the concentration of the monoclonal antibody on the surface of the polystyrene NP was far lower than that of the polyclonal antibody (Fig. 8(A)–(D)), which also produced a larger diameter in polystyrene NP, observed using differential centrifugal sedimentation (DCS) (Fig. 8(E)). These results suggest that the transferrin (and thus the hard protein corona in general) is randomly organized on the surface of polystyrene NPs in various conformations, limiting the availability of an epitope for binding to its corresponding receptor.\nGiven the findings by various groups discussed above, future investigations in this area should focus on optimization of coronamediated NP targeting strategies, both in terms of the recruitment of the desired plasma proteins and also their accessibility and ori-\nrstanding of the protein corona at the nano-bio interfaces, Nano\nentation/folding/conformation in the corona layer. In other words, to fabricate NPs with high targeting efficacy, we must gain a thorough understanding of the composition of the outer layer of the corona and the accessibility of the functional motifs of desirable\nFig. 10. Flow cytometry results indicating the uptake of various cysteine-biotin-conjugated silica NPs (Cys-Bio-NPs) by adenocarcinoma human alveolar basal epithelial cells in serum-free medium (SF-DMEM). NP at concentrations of (A) 50 and (B) 500 g/mL with bar graphs (B and D) showing geometrical mean fluorescence in different s additi a\nS [68].\np m i\nC a\no p t b\nt w b u w [ t m i\ntates (including pristine), after human plasma treatment (10% and 50%) and after\ns mean ± SD (n = 3), * denotes (p-value < 0.05), and N.S. denotes not significant.\nource: Printed with permission from American Chemical Society publishing group\nroteins to target cell receptors. In that regard, in vivo experiments ight prove valuable to fully grasp the impact of all phenomena\nnvolved, in complete living organisms.\norona-free interfaces for high-yield targeting and delivery pplications\nAnother proposed strategy to enhance the targeting capability f NPs is to coat them with materials that inhibit interaction with roteins. If proteins are prevented from masking the engineered argeting ligands on the NP surface, there should be no coronaased loss of targeting efficacy.\nOne of the early materials proposed for preventing the formaion of the corona was non-charged poly(ethylene glycols) (PEGs), hich have good resistance against non-specific adsorption mainly ecause of their hydrogen bonding with water [59]. However, evalations of coronas formed on PEGylated surfaces revealed they ere composed mainly of fibrinogen, IgG, and apolipoprotein E\nPlease cite this article in press as: M. Mahmoudi, et al., Emerging unde Today (2016), http://dx.doi.org/10.1016/j.nantod.2016.10.005\n60–62]. As PEG clearly could not satisfy the urgent need for fabricaion of corona-free NPs, researchers looking for another candidate\naterial decided to pursue the promise of zwitterionic coatings in nhibiting corona formation [63,64]. In very early evaluations, zwit-\non of free biotin (to block specific uptake by biotin receptors). The data are shown\nterionic coatings demonstrated that they offered an alternative to increase NPs’ biocompatibility and blood circulation time [65,66]. Using a series of zwitterionic NPs with different hydrophobicities, Moyano et al. [67] determined that no hard protein corona layer was formed. Therefore, zwitterionic NPs do facilitate the direct interaction of synthetic and biological components without the interference of a protein corona. This makes the combination of zwitterionic NPs with targeting ligands one of the most promising candidate strategies for targeting applications, mainly because they may be able to bypass the shielding effects (i.e., covering the targeting ligands) of the protein corona.\nTo probe the targeting efficacy of zwitterionic-coated NPs, Safavi et al. [68] fabricated biotin-cysteine-conjugated silica NPs; biotin was selected as the proper targeting molecule, and cysteine was used as a zwitterionic ligand to inhibit corona formation. The targeting capability of the biotin-cysteine-conjugated silica NPs and control targeted NPs (i.e., with biotin but without cysteine) were compared using modified silicon wafer substrates with streptavidin, which is a biotin receptor (Fig. 9). The zwitterionic-coated\nrstanding of the protein corona at the nano-bio interfaces, Nano\nNPs showed significantly higher targeting efficacy than the control NPs after incubation with human plasma. Similar results were obtained regarding the uptake properties of NPs by tumor cell lines\nFig. 11. (A) Schematic showing the chemical structure of the pH-responsive (AuNP1) and control (AuNP2) gold nanoparticles and cartoon showing how pH-responsive nanoparticles can enhance cellular uptake in the tumor microenvironment (with lower pH than the normal tissue). (B) Variation of zeta potential of AuNPs1 and AuNPs2 against pH values showing the cationic structure of AuNPs1 in acidic pH. (C) Cellular uptake of AuNPs1 and AuNPs2 after 3 h incubation with HeLa and HMEC-1 cells showing the significantly higher uptake of AuNPs1 in HeLa cells at lower pH. (D) Viability of HeLa cells after incubation with AuNPs1 and AuNPs2 (for 72 h) revealing the cytotoxicity o ubate m\nS\nt d g\nb N b m d t e c N h i t i c p t\nf AuNPs1 in the low pH. (E) Transmission electron microscopy images of the inc embrane at normal pH and their endosomal uptake at lower pH 6.0.\nource: Printed with permission from Wiley publishing group [74].\nhat overexpress biotin receptors (Fig. 10). These results clearly emonstrate the utility of zwitterionic coating in facilitating tareting of NPs.\nIt is now well understood that the uptake rate of cationic NPs y cells is significantly higher than that of anionic or neutral Ps [69–71], mainly because of the strong Coulombic interactions etween cationic NPs and the anionic cell membrane. As the tumor icroenvironment has lower pH (∼6.5) than normal tissue [72,73], evelopment of pH-responsive zwitterionic NPs with the capability o become cationic in the cancer microenvironment is of great interst. This platform could significantly enhance the NPs’ uptake by ancerous cells, greatly reducing side effects in normal tissue. Such Ps would have promising therapeutic applications due to their igh-yield tumor targeting, cancerous cell uptake, and cytotoxicty. Mizuhara et al. [74] proposed an innovative method to fabricate hese NPs using a zwitterionic alkoxyphenyl acylsulfonamide coat-\nPlease cite this article in press as: M. Mahmoudi, et al., Emerging unde Today (2016), http://dx.doi.org/10.1016/j.nantod.2016.10.005\nng (Fig. 11(A)). The acylsulfonamide plays a role similar to that of arboxylic acid groups in response to changes in pH value [75]. The H responsivity of acylsulfonamide group is controlled by the funcional group attached to the sulfonyl group. Gold-coated NPs with\nd HeLa cells with AuNPs1 (for 3 h) showing the nanoparticles present on the cell\nthis zwitterionic ligand showed formation of cationic NPs at tumor pH as a result of this ligand structure. In addition to this ligand, another zwitterionic gold NP (i.e., alkyl analogue) was used as control (see Fig. 11(A)). Zeta potential screening of those NPs at various pH revealed the capability of these pH-sensitive particles to assume a cationic state (Fig. 11(B)). Probing the cellular uptake of both NPs by two cell lines (i.e., human cervical cancer cells/HeLa) and human microvascular endothelial cells/ (HMEC-1) revealed that the HeLa cells showed significant uptake of pH-sensitive NPs at low pH, while this effect was not seen in HMEC-1 cells (Fig. 11(C)). This is presumably due to the “cell vision” effect [76,77]. It is noteworthy that cell vision is a variation of the detoxification strategies that any cell can use in response to toxins, drugs, and NPs [78]. In the lower pH, the cationic NPs caused significantly higher toxicity in the HeLa cells compared to the control NPs (Fig. 11(D)) because of the significantly higher uptake of the pH-sensitive NPs into the cells (Fig. 11(E)).\nrstanding of the protein corona at the nano-bio interfaces, Nano\nIn a very recent report, Kang et al. [79] developed an innovative zwitterionic nanocarrier for high-yield delivery of anticancer drugs to tumor sites with negligible side effects to normal cells, mainly due to the rapid renal clearance of untargeted nanocar-\nF DPL) z\nS\nr r r w c f e t i ( p e f t e c w i n t r b\nig. 12. Schematic representation of the zwitterionic cyclodextrins-polylysine (C witterionic near-infrared fluorophore (i.e., ZW800-1C).\nource: Printed with permission from Wiley publishing group [79].\niers. As mentioned earlier, zwitterionic properties were used to educe the protein corona on the surface of nanocarriers and thus educe non-specific uptake by normal cells and immune system hile enhancing the targeting capability of carriers toward the ancerous cells. For renal clearance of the untargeted nanocarriers rom various tissues/organs, the hydrodynamic size of nanocarrirs was designed to be ∼<5.5 nm. The nanocarriers were made of hree parts: -polylysine (EPL) for zwitterionic modifications, nearnfrared (NIR) fluorophores for bioimaging, and -cyclodextrins -CDs) for drug delivery (see Fig. 12 for details). Due to the low rotein adsorption to their surface, these zwitterionic nanocarrirs escaped the immune system and showed significant capability or high-yield targeting of the tumor site in vivo (in both gastroinestinal stromal tumor (GIST)-bearing xenograft and genetically ngineered mice; see Fig. 13(A)–(C)). It is noteworthy that a fluoresent dye (Cy3 N-hydroxysuccinimide Ester)-conjugated imatinib as used in the nanocarrier to both target the tyrosine-kinase nhibitor for treating GIST [80] and track the biodistribution of the anocarriers. The results (Fig. 13(B)) revealed that the nanocarriers\nPlease cite this article in press as: M. Mahmoudi, et al., Emerging unde Today (2016), http://dx.doi.org/10.1016/j.nantod.2016.10.005\nhat were distributed in other tissues (except tumor tissue) were apidly cleared by the kidney and completely excreted through the ladder 24 h after administration.\nnanocarrier. (B) The synthesis procedure of zwitterionic CDPL conjugated with\nHistopathological analyses of the tumor site (Fig. 13(D)) were performed to probe distribution of the drug-loaded nanocarriers in the tumor microenvironment. Fluorescence images of the nanocarriers revealed their accumulation in the boundaries of tumoral regions; the drug released by those carriers penetrated the intratumor environment. These findings clearly demonstrated that zwitterionic nanocarriers are capable of delivering hydrophobic drugs to the tumor site. Due to the acidic environment of tumor site [72,73], the drug can then be released by forming a stable inclusion complex [79]. These newly developed zwitterionic nanocarriers are paving the way for theranostic nanoplatforms for safe, high-yield delivery of a wide variety of anticancer drugs.\nPersonalized protein corona: new challenge at the nanobio interface\nIt has been shown that the protein source (i.e., human plasma, human serum, and fetal bovine serum) has a significant effect on the composition of the protein corona [81]; in turn, different corona\nrstanding of the protein corona at the nano-bio interfaces, Nano\ncompositions cause considerable changes in cellular uptake and intracellular traficking of NPs [82,83].\nIt is well-recognized that various diseases may change the concentration/conformation of human plasma proteins; these include\nFig. 14. (A) Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) image of the corona profiles at the surface of liposomes obtained from incubations of liposomes with human plasma proteins of various healthy donors. (B) Histograms representing the total lane intensity of protein corona profiles of various healthy donors. (C) H ght. (D w\nS\ns l\np p c\nN d r h n b d s f s c g F a s t i o i f\ni c c\nC\ni t\nistogram of the alterations in band intensity according to proteins’ molecular wei ere normalized to the ladder intensity.\nource: Printed with permission from Elsevier publishing group [105].\ntrated that the clearance of doxorubicin liposomes was twofold ower in patients over 60 years old compared to younger patients.\nIt is increasingly being accepted that variation in plasma roteins caused by disease type can significantly change the comosition of the protein corona at the surface of NPs [14,22,97] and onsequently their interactions with biological species [16,98,99].\nFor instance, it was demonstrated that silica and polystyrene Ps affect the conformation of fibrinogen protein in the corona prouced by healthy individuals, substantially promoting the body’s elease of inflammatory cytokines [26]. In contrast, the corona of ypofibrinogenemia patients on the surface of the same NPs did ot induce inflammatory cytokine release. This means that the iological identity (i.e., protein corona profile) of NPs should be esigned to closely correspond to the disease type. Therefore, NPs hould undergo disease-specific and even patient-specific design or highly efficient and safe clinical applications. Recent findings how that even healthy individuals may have different plasma ompositions due to variation in their genetic background, age, ender, post-translational modification, and life style [100–105]. or instance, Colapicchioni et al. [105] showed significant variation mong the protein corona profiles of healthy donors (Fig. 14). This trongly suggests that in order to accelerate the clinical translaion of NPs, researchers in the field should clearly report detailed nformation regarding the human serum/plasma (including type f disease, age, and gender) they use for each study; such precise nformation will minimize misinterpretation of protein corona data or in vivo applications [106].\nOverlooking the central role of the newly understood “personalzed protein corona” may be the major cause for the disappointing linical results of the very few nanobio products that have reached linical-stage evaluation [29].\nonclusions and future perspectives\nPlease cite this article in press as: M. Mahmoudi, et al., Emerging unde Today (2016), http://dx.doi.org/10.1016/j.nantod.2016.10.005\nAs shown above, the protein corona directly affects the biologcal identity of nanoparticles, which may be totally different from heir laboratory-designed identity. Such variation in nanoparti-\n) Histogram of the relative densitometry of four major bands. The band intensities\ncle’ identity can significantly reduce expected drug targeting yield, drug release profile, and therapeutic efficacy. Current research in the field is focused on the development of new strategies to create nanoparticles with predictable/controllable biological identity. Among various surface coatings, zwitterionics have demonstrated a very promising role in inhibiting corona formation, enhancing both cell targeting and non-specific uptake by the immune system. In addition, coating a nanoparticle with specific proteins is another promising way to control corona formation (mainly via protein–protein interactions) and enhance targeting by recruiting targeting proteins from plasma. We expect that future efforts in the field will be centered on development of multifunctional zwitterionic coatings for fabrication of safe and corona-free NPs for high-yield therapeutic efficacy. In addition, the optimization of nanoparticles’ surface properties by either protein pre-coating or specific chemical modifications can avoid the inhibitory role of protein corona by achieving high possible recruitment of the targeting proteins from plasma with highest accessibility of their active sites to the cell receptors.\nAs the majority of nanoparticles are injected intravenously, they have substantial interactions with endothelial cells. Recent findings revealed that TiO2 nanomaterials can affect the functionality of VE-cadherin (i.e., endothelial cells’ adherens junction protein), thereby causing endothelial cell leakiness [107]. To design safe nanoparticles with high therapeutic efficacy, the effect of the protein corona on this newly discovered non-receptor-mediated mechanism should be carefully probed. The resulting information could help scientists design nanoparticles that interact minimally with VE-cadherin to diminish the risk of induced endothelial cell leakiness.\nWe also believe that a more comprehensive understanding of the personalized protein corona is necessary to advance the field and accelerate more predictable clinical translation. More\nrstanding of the protein corona at the nano-bio interfaces, Nano\nspecifically, nanoparticles should be custom-designed for specific diseases, as each disease may significantly affect the composition of the protein corona, changing its interactions with biological systems.\nING ModelN no To\nC\nT\nA\nH m S D e N\nR\nARTICLEANTOD-549; No. of Pages 16 M. Mahmoudi et al. / Na\nonflict of interest\nO.C.F. declares financial interests in Selecta Biosciences, Tarveda herapeutics and Placon Therapeutics.\ncknowledgement\nThis work was supported by the grants US National Institutes of ealth (NIH) CA151884 (O.C.F.) and EB015419 (O.C.F.); US Departent of Defense (DoD) Prostate Cancer Research Program (PCRP) ynergistic Idea Development Award W81XWH 15 1 0728 (O.C.F.); avid Koch Prostate Cancer Foundation (PCF) Award in Nanothrapeutics (O.C.F.); Movember PCF Challenge Award (O.C.F.); and ational Research Foundation of Korea (K1A1A2048701) (O.C.F.).\neferences\n[1] K.K. Jain, BMC Med. 8 (2010) 83. [2] M.P. Monopoli, C. Åberg, A. Salvati, K.A. Dawson, Nat. Nanotechnol. 7 (2012)\n779–786. [3] M. Mahmoudi, S.E. Lohse, C.J. Murphy, A. Fathizadeh, A. Montazeri, K.S.\nSuslick, Nano Lett. 14 (2013) 6–12. [4] D. Walczyk, F.B. Bombelli, M.P. Monopoli, I. Lynch, K.A. Dawson, J. Am.\nChem. Soc. 132 (2010) 5761–5768. [5] M. Mahmoudi, Int. J. Biochem. Cell Biol. 75 (2016) 141–142. [6] M. Mahmoudi, I. Lynch, M.R. Ejtehadi, M.P. Monopoli, F.B. Bombelli, S.\nLaurent, Chem. Rev. 111 (2011) 5610. [7] S. Tenzer, D. Docter, J. Kuharev, A. Musyanovych, V. Fetz, R. Hecht, F. Schlenk,\nD. Fischer, K. Kiouptsi, C. Reinhardt, Nat. Nanotechnol. 8 (2013) 772–781. [8] A.E. Nel, L. Mädler, D. Velegol, T. Xia, E.M. Hoek, P. Somasundaran, F.\nKlaessig, V. Castranova, M. Thompson, Nat. Mater. 8 (2009) 543–557. [9] C.D. Walkey, J.B. Olsen, H. Guo, A. Emili, W.C. Chan, J. Am. Chem. Soc. 134\n(2012) 2139–2147. [10] J. Lazarovits, Y.Y. Chen, E.A. Sykes, W.C.W. Chan, Chem. Commun. 51 (2015)\n2756–2767. [11] C.Y. Tay, M.I. Setyawati, J. Xie, W.J. Parak, D.T. Leong, Adv. Funct. Mater. 24\n(2014) 5936–5955. [12] A.A. Saie, M. Ray, M. Mahmoudi, V.M. Rotello, Engineering the\nNanoparticle-Protein Interface for Cancer Therapeutics, Nanotechnology-Based Precision Tools for the Detection and Treatment of Cancer, Springer International Publishing, 2015, pp. 245–273.\n[13] S. Zanganeh, R. Spitler, M. Erfanzadeh, A.M. Alkilany, M. Mahmoudi, Int. J. Biochem. Cell Biol. 75 (2016) 143–147. [14] M.I. Setyawati, C.Y. Tay, D. Docter, R.H. Stauber, D.T. Leong, Chem. Soc. Rev. 44 (2015) 8174–8199. [15] G. Caracciolo, Nanomed. Nanotech. Biol. Med. 11 (2015) 543–557. [16] M. Azhdarzadeh, A.A. Saei, S. Sharifi, M.J. Hajipour, A.M. Alkilany, M.\nSharifzadeh, F. Ramazani, S. Laurent, A. Mashaghi, M. Mahmoudi, Nanomedicine 10 (2015) 2931–2952.\n[17] L. Bregoli, D. Movia, J.D. Gavigan-Imedio, J. Lysaght, J. Reynolds, A. Prina-Mello, Nanomed. Nanotechnol. Biol. Med. 12 (2016) 81–103. [18] C. Corbo, R. Molinaro, A. Parodi, N.E.T. Furman, F. Salvatore, E. Tasciotti, Nanomedicine 11 (2016) 81–100. [19] S. Schöttler, K. Landfester, V. Mailänder, Angew. Chem. Int. Ed. 55 (2016) 8806–8815. [20] G. Caracciolo, O.C. Farokhzad, M. Mahmoudi, Trends Biotechnol. (2016), http://dx.doi.org/10.1016/j.tibtech.2016.08.011 (in press. [21] M.A. Miller, S. Gadde, C. Pfirschke, C. Engblom, M.M. Sprachman, R.H. Kohler, K.S. Yang, A.M. Laughney, G. Wojtkiewicz, N. Kamaly, Sci. Transl. Med. 7 (2015), 314ra183–314ra183. [22] M.J. Hajipour, S. Laurent, A. Aghaie, F. Rezaee, M. Mahmoudi, Biomater. Sci. 2 (2014) 1210–1221. [23] P.M. Kelly, C. Åberg, E. Polo, A. O’Connell, J. Cookman, J. Fallon, Ž. Krpetić, K.A. Dawson, Nat. Nanotechnol. 10 (2015) 472–479. [24] A. Albanese, C.D. Walkey, J.B. Olsen, H. Guo, A. Emili, W.C.W. Chan, ACS Nano 8 (2014) 5515–5526. [25] K. Saha, M. Rahimi, M. Yazdani, S.T. Kim, D.F. Moyano, S. Hou, R. Das, R. Mout, F. Rezaee, M. Mahmoudi, V.M. Rotello, ACS Nano 10 (2016) 4421–4430. [26] M. Rahman, M. Mahmoudi, SPIE BiOS, International Society for Optics and Photonics, 2015, pp. 93380V-93380V-93388. [27] F. Sonvico, S. Mornet, S. Vasseur, C. Dubernet, D. Jaillard, J. Degrouard, J. Hoebeke, E. Duguet, P. Colombo, P. Couvreur, Bioconjug. Chem. 16 (2005) 1181–1188. [28] S. Shanehsazzadeh, C. Gruettner, A. Lahooti, M. Mahmoudi, B.J. Allen, M. Ghavami, F.J. Daha, M.A. Oghabian, Contrast Media Mol. Imaging 10 (2015) 225–236.\nPlease cite this article in press as: M. Mahmoudi, et al., Emerging unde Today (2016), http://dx.doi.org/10.1016/j.nantod.2016.10.005\n[29] H. Ledford, Nature 533 (2016) 304–305. [30] S. Laurent, M. Mahmoudi, Int. J. Mol. Epidemiol. Genet. 2 (2011) 367–390. [31] A. Salvati, A.S. Pitek, M.P. Monopoli, K. Prapainop, F.B. Bombelli, D.R. Hristov,\nP.M. Kelly, C. Åberg, E. Mahon, K.A. Dawson, Nat. Nanotechnol. 8 (2013) 137–143.\nPRESS day xxx (2016) xxx–xxx 15\n[32] V. Mirshafiee, M. Mahmoudi, K. Lou, J. Cheng, M.L. Kraft, Chem. Commun. 49 (2013) 2557–2559. [33] K. Strebhardt, A. Ullrich, Nat. Rev. Cancer 8 (2008) 473–480. [34] J. Shi, Z. Xiao, N. Kamaly, O.C. Farokhzad, Acc. Chem. Res. (2011). [35] R.S. Zolot, S. Basu, R.P. Million, Nat. Rev. Drug Discov. 12 (2013) 259–260. [36] Z. Bakhtiary, A.A. Saei, M.J. Hajipour, M. Raoufi, O. Vermesh, M. Mahmoudi,\nNanomed. Nanotech. Biol. Med. 12 (2016) 287–307. [37] H. Chen, S. Kim, L. Li, S. Wang, K. Park, J.-X. Cheng, Proc. Natl. Acad. Sci. U. S.\nA. 105 (2008) 6596–6601. [38] H. Chen, S. Kim, W. He, H. Wang, P.S. Low, K. Park, J.-X. Cheng, Langmuir 24\n(2008) 5213–5217. [39] A. Cifuentes-Rius, H. de Puig, J.C.Y. Kah, S. Borros, K. Hamad-Schifferli, ACS\nNano 7 (2013) 10066–10074. [40] S. Behzadi, V. Serpooshan, R. Sakhtianchi, B. Müller, K. Landfester, D. Crespy,\nM. Mahmoudi, Colloids Surf. B 123 (2014) 143–149. [41] R. Mout, D.F. Moyano, S. Rana, V.M. Rotello, Chem. Soc. Rev. 41 (2012)\n2539–2544. [42] V. Mirshafiee, R. Kim, S. Park, M. Mahmoudi, M.L. Kraft, Biomaterials 75\n(2016) 295–304. [43] T. Mizuhara, D.F. Moyano, V.M. Rotello, Nano Today 11 (2016) 31–40. [44] C.S. Kim, N.D. Le, Y. Xing, B. Yan, G.Y. Tonga, C. Kim, R.W. Vachet, V.M.\nRotello, Adv. Healthc. Mater. 3 (2014) 1200–1202. [45] Y. Jiang, S. Huo, T. Mizuhara, R. Das, Y.-W. Lee, S. Hou, D.F. Moyano, B.\nDuncan, X.-J. Liang, V.M. Rotello, ACS Nano 9 (2015) 9986–9993. [46] C.-F. Wang, E.M. Mäkilä, C. Bonduelle, J. Rytkönen, J. Raula, S. Almeida, A.\nNärvänen, J.J. Salonen, S. Lecommandoux, J.T. Hirvonen, H.A. Santos, ACS Appl. Mater. Interfaces 7 (2015) 2006–2015. [47] L.A. Trouw, A.A. Bengtsson, K.A. Gelderman, B. Dahlbäck, G. Sturfelt, A.M. Blom, J. Biol. Chem. 282 (2007) 28540–28548. [48] J.H. Webb, A.M. Blom, B. Dahlbäck, J. Immunol. 169 (2002) 2580–2586. [49] S. Schöttler, G. Becker, S. Winzen, T. Steinbach, K. Mohr, K. Landfester, V.\nMailänder, F.R. Wurm, Nat. Nanotechnol. 11 (2016) 372–377. [50] M.A. Miller, Y.-R. Zheng, S. Gadde, C. Pfirschke, H. Zope, C. Engblom, R.H.\nKohler, Y. Iwamoto, K.S. Yang, B. Askevold, N. Kolishetti, M. Pittet, S.J. Lippard, O.C. Farokhzad, R. Weissleder, Nat. Commun. 6 (2015).\n[51] C. Von Mering, R. Krause, B. Snel, M. Cornell, S.G. Oliver, S. Fields, P. Bork, Nature 417 (2002) 399–403. [52] J. Kreuter, T. Hekmatara, S. Dreis, T. Vogel, S. Gelperina, K. Langer, J. Control. Release 118 (2007) 54–58. [53] L. Allen, A. Aderem, J. Exp. Med. 184 (1996) 627–637. [54] P. Selvaraj, W.F. Rosse, R. Silber, Nature 333 (1988) 9. [55] V. Mirshafiee, R. Kim, M. Mahmoudi, M.L. Kraft, Int. J. Biochem. Cell Biol. 75\n(2016) 188–195. [56] G. Caracciolo, S. Palchetti, V. Colapicchioni, L. Digiacomo, D. Pozzi, A.L.\nCapriotti, G. La Barbera, A. Laganà, Langmuir 31 (2015) 10764–10773. [57] Y. Cheng, O. Zak, P. Aisen, S.C. Harrison, T. Walz, Cell 116 (2004) 565–576. [58] A.B. Mason, S.L. Byrne, S.J. Everse, S.E. Roberts, N.D. Chasteen, V.C. Smith, R.T.\nMacGillivray, B. Kandemir, F. Bou-Abdallah, J. Mol. Recognit. 22 (2009) 521–529.\n[59] R. Wang, H. Kreuzer, M. Grunze, J. Phys. Chem. B 101 (1997) 9767–9773. [60] H.R. Kim, K. Andrieux, C. Delomenie, H. Chacun, M. Appel, D. Desmaële, F.\nTaran, D. Georgin, P. Couvreur, M. Taverna, Electrophoresis 28 (2007) 2252–2261.\n[61] J.L. Perry, K.G. Reuter, M.P. Kai, K.P. Herlihy, S.W. Jones, J.C. Luft, M. Napier, J.E. Bear, J.M. DeSimone, Nano Lett. 12 (2012) 5304–5310. [62] R. Gref, M. Lück, P. Quellec, M. Marchand, E. Dellacherie, S. Harnisch, T. Blunk, R.H. Müller, Colloids Surf. B 18 (2000) 301–313. [63] K.P. García, K. Zarschler, L. Barbaro, J.A. Barreto, W. O’Malley, L. Spiccia, H. Stephan, B. Graham, Small 10 (2014) 2516–2529. [64] G. Jia, Z. Cao, H. Xue, Y. Xu, S. Jiang, Langmuir 25 (2009) 3196–3199. [65] F. Aldeek, M.H. Muhammed, G. Palui, N. Zhan, H. Mattoussi, ACS Nano 7\n(2013) 2509–2521. [66] R.R. Arvizo, O.R. Miranda, D.F. Moyano, C.A. Walden, K. Giri, R. Bhattacharya,\nJ.D. Robertson, V.M. Rotello, J.M. Reid, P. Mukherjee, PLoS One 6 (2011) e24374.\n[67] D.F. Moyano, K. Saha, G. Prakash, B. Yan, H. Kong, M. Yazdani, V.M. Rotello, ACS Nano 8 (2014) 6748–6755. [68] R. Safavi-Sohi, S. Maghari, M. Raouf, S.M. JalaliI, M.J. Hajipour, A. Ghassempour, M. Mahmoudi, ACS Appl. Mater. Interfaces 8 (2016) 22808–22818. [69] A. Verma, F. Stellacci, Small 6 (2010) 12–21. [70] M. De, P.S. Ghosh, V.M. Rotello, Adv. Mater. 20 (2008) 4225–4241. [71] C.M. Goodman, C.D. McCusker, T. Yilmaz, V.M. Rotello, Bioconjug. Chem. 15\n(2004) 897–900. [72] G. Helmlinger, F. Yuan, M. Dellian, R.K. Jain, Nat. Med. 3 (1997) 177–182. [73] R.A. Cardone, V. Casavola, S.J. Reshkin, Nat. Rev. Cancer 5 (2005) 786–795. [74] T. Mizuhara, K. Saha, D.F. Moyano, C.S. Kim, B. Yan, Y.K. Kim, V.M. Rotello,\nAngew. Chem. Int. Ed. 54 (2015) 6567–6570. [75] P.K. Chakravarty, E.M. Naylor, A. Chen, R.S. Chang, T.-B. Chen, K.A. Faust, V.J.\nLotti, S.D. Kivlighn, R.A. Gable, J. Med. Chem. 37 (1994) 4068–4072. [76] M. Mahmoudi, S.N. Saeedi-Eslami, M.A. Shokrgozar, K. Azadmanesh, M.\nrstanding of the protein corona at the nano-bio interfaces, Nano\nHassanlou, H.R. Kalhor, C. Burtea, B. Rothen-Rutishauser, S. Laurent, S. Sheibani, Nanoscale 4 (2012) 5461–5468.\n[77] M. Mahmoudi, S. Laurent, M.A. Shokrgozar, M. Hosseinkhani, ACS Nano 5 (2011) 7263–7276.\nING ModelN 1 no To\nr n s\nthe Boston University School of Medicine and his M.B.A. from the Massachusetts Institute of Technology. Omid\nFarokhzad’s research is focused on the development of therapeutic nanoparticle technologies and the high-throughput combinatorial nanoengineering of multifunctional nanoparticles for medical applications.\nARTICLEANTOD-549; No. of Pages 16 6 M. Mahmoudi et al. / Na\n[78] S. Laurent, C. Burtea, C. Thirifays, U.O. Häfeli, M. Mahmoudi, PLoS One 7 (2012) e29997. [79] H. Kang, J. Gravier, K. Bao, H. Wada, J.H. Lee, Y. Baek, G. El Fakhri, S. Gioux, B.P. Rubin, J.L. Coll, Adv. Mater. 28 (2016) 8162–8168. [80] S. Béni, Z. Szakács, O. Csernák, L. Barcza, B. Noszál, Eur. J. Pharm. Sci. 30 (2007) 167–174. [81] S. Laurent, C. Burtea, C. Thirifays, F. Rezaee, M. Mahmoudi, J. Colloid Interface Sci. 392 (2013) 431–445. [82] H.Y. Mao, S. Laurent, W. Chen, O. Akhavan, M. Imani, A.A. Ashkarran, M. Mahmoudi, Chem. Rev. 113 (2013) 3407–3424. [83] S. Schöttler, K. Klein, K. Landfester, V. Mailänder, Nanoscale 8 (2016) 5526–5536. [84] L. Kennedy, T.D. Mehl, E. Elder, M. Varghese, T.J. Merimee, Diabetes 31 (1982) 52–56. [85] G. Engström, P. Lind, B. Hedblad, L. Stavenow, L. Janzon, F. Lindgärde, Circulation 105 (2002) 2632–2637. [86] Y.-P. Lin, C.-Y. Yang, C.-C. Liao, W.-C. Yu, C.-W. Chi, C.-H. Lin, PLoS One 7 (2012) e40232. [87] S. Acharya, D. Dimichele, Haemophilia 14 (2008) 1151–1158. [88] K.S. Kelly-Spratt, S.J. Pitteri, K.E. Gurley, D. Liggitt, A. Chin, J. Kennedy, C.-H.\nWong, Q. Zhang, T.B. Buson, H. Wang, PLoS One 6 (2011) e19721. [89] D. Brown, J. Clin. Pathol. 55 (2002) 1. [90] K. Blennow, H. Hampel, M. Weiner, H. Zetterberg, Nat. Rev. Neurol. 6 (2010)\n131–144. [91] P.M. Ridker, N.J. Brown, D.E. Vaughan, D.G. Harrison, J.L. Mehta, Circulation\n109 (2004), IV-6-IV-19. [92] O.M. El-Agnaf, S.A. Salem, K.E. Paleologou, M.D. Curran, M.J. Gibson, M.G.\nSchlossmacher, D. Allsop, FASEB J. 20 (2006) 419–425. [93] S.M. Hanash, S.J. Pitteri, V.M. Faca, Nature 452 (2008) 571–579. [94] J. Wei, W. Gao, C.-J. Zhu, Y.-Q. Liu, Z. Mei, T. Cheng, Y.-Q. Shu, Chin. J. Cancer\n30 (2011) 407. [95] H.B. Salt, Ann. Rheum. Dis. 10 (1951) 46. [96] N.M. La-Beck, B.A. Zamboni, A. Gabizon, H. Schmeeda, M. Amantea, P.A.\nGehrig, W.C. Zamboni, Cancer Chemother. Pharmacol. 69 (2012) 43–50. [97] G. Caracciolo, D. Caputo, D. Pozzi, V. Colapicchioni, R. Coppola, Colloids Surf.\nB 123 (2014) 673–678. [98] M.J. Hajipour, J. Raheb, O. Akhavan, S. Arjmand, O. Mashinchian, M. Rahman,\nM. Abdolahad, V. Serpooshan, S. Laurent, M. Mahmoudi, Nanoscale 7 (2014) 8978–8994.\n[99] S. Palchetti, D. Pozzi, M. Mahmoudi, G. Caracciolo, J. Mater. Chem. B (2016). [100] J. Brewer, O. Gurel, Nanotechnol. Law Bus. 6 (2009) 45. [101] G.P. Chrousos, Nat. Rev. Endocrinol. 5 (2009) 374–381. [102] D. Nedelkov, U.A. Kiernan, E.E. Niederkofler, K.A. Tubbs, R.W. Nelson, Proc.\nNatl. Acad. Sci. U. S. A. 102 (2005) 10852–10857. [103] N.L. Anderson, N.G. Anderson, Mol. Cell. Proteom. 1 (2002) 845–867. [104] Z.M. Ruggeri, T.S. Zimmerman, J. Clin. Investig. 65 (1980) 1318. [105] V. Colapicchioni, M. Tilio, L. Digiacomo, V. Gambini, S. Palchetti, C. Marchini,\nD. Pozzi, S. Occhipinti, A. Amici, G. Caracciolo, Int. J. Biochem. Cell Biol. 75 (2016) 180–187.\n[106] A.M. Alkilany, N.N. Mahmoud, F. Hashemi, M.J. Hajipour, F. Farvadi, M. Mahmoudi, Chem. Res. Toxicol. 29 (2016) 943–948. [107] M. Setyawati, C. Tay, S. Chia, S. Goh, W. Fang, M. Neo, H. Chong, S. Tan, S. Loo, K. Ng, Nat. Commun. 4 (2013) 1673.\nMorteza Mahmoudi is an instructor in the Laboratory of Nanomedicine and Biomaterials at Harvard Medical School (HMS) and Brigham and Women’s Hospital (BWH). He is also the director of the NanoBio Interaction Laboratory (www.biospion.com) at Tehran University of Medical Sciences. He received his Ph.D. working the development of ultra-safe superparamagnetic iron oxide nanoparticles for various biomedical applications at Sharif University of Technologyin 2009. He then completed his postdoctoral research training at Stanford Medical School. Dr. Mahmoudi’s diverse engineering and medical train-\nPlease cite this article in press as: M. Mahmoudi, et al., Emerging unde Today (2016), http://dx.doi.org/10.1016/j.nantod.2016.10.005\ning uniquely prepared him to perform multi-disciplinary research at the convergence of physics, chemistry, mate-\nials, biology, and medicine, which he now applies to the development of smart anobio-materials for cancer therapy with predictable/controllable protein corona tructure.\nPRESS day xxx (2016) xxx–xxx\nNicolas Bertrand is an Assistant Professor at Université Laval in Quebec City, Canada. His laboratory is situated in the Centre de Recherche du CHU de Quebec. A pharmacist by training, he received his PhD in Pharmaceutical Sciences from Université de Montréal, in 2011. Between 2011 and 2014, he was a postdoctoral fellow in the laboratory of Prof. Robert Langer, at the David H Koch Institute for Integrative Cancer Research at MIT, in Cambridge, MA. His research focuses on understanding the interactions between nanomaterials and complex environments, notably using pharmacokinetics, to create more efficient drug delivery systems.\nDr Harshal R. Zope was born in Bhusawal, India in 1986. He pursued his interest in research by joining the Institute of Biotechnology and Bioinformatics, University of Pune, India, from which he obtained a 5-year integrated M.Sc. degree in Biotechnology (2008) as well as a M. Tech degree in Biotechnology (2009). He pursued his PhD research at Leiden University under the supervision of Dr Alexander Kros (Feb 2010). During his PhD, he worked on peptide-based functional biomaterials for various applications such as understanding membrane fusion, drug delivery, and vaccine development. Currently, Dr. Zope is a Postdoctoral fellow at the Laboratory of Nanomedicine, Harvard Medical School/Brigham and Women’s Hospital\n(HMS/BWH), Boston, USA. In the group of Prof. Omid Farokhzad and Prof. Jinjun Shi, he is developing a novel nanotechnology platform for HIV vaccine and cancer therapy.\nOmid Farokhzad is an associate professor at Harvard Medical School (HMS) and a physician–scientist at Brigham and Women’s Hospital (BWH). He is the director of the Laboratory of Nanomedicine and Biomaterials (http://farokhzad.bwh.harvard.edu), a faculty member of the Brigham Research Institute Cancer Research Center, and a member of the Dana Farber/Harvard Cancer Center. He completed his postgraduate clinical and postdoctoral research training at BWH/HMS and the Massachusetts Institute of Technology in the laboratory of Institute Professor Robert Langer. He received his M.D. and M.A. from\nrstanding of the protein corona at the nano-bio interfaces, Nano"
    } ],
    "references" : [ {
      "title" : "BMC Med",
      "author" : [ "K.K. Jain" ],
      "venue" : "8 ",
      "citeRegEx" : "1",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Nat",
      "author" : [ "M.P. Monopoli", "C. Åberg", "A. Salvati", "K.A. Dawson" ],
      "venue" : "Nanotechnol. 7 ",
      "citeRegEx" : "2",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Nano Lett",
      "author" : [ "M. Mahmoudi", "S.E. Lohse", "C.J. Murphy", "A. Fathizadeh", "A. Montazeri", "K.S. Suslick" ],
      "venue" : "14 ",
      "citeRegEx" : "3",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Chem",
      "author" : [ "D. Walczyk", "F.B. Bombelli", "M.P. Monopoli", "I. Lynch", "K.A. Dawson", "J. Am" ],
      "venue" : "Soc. 132 ",
      "citeRegEx" : "4",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Int",
      "author" : [ "M. Mahmoudi" ],
      "venue" : "J. Biochem. Cell Biol. 75 ",
      "citeRegEx" : "5",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Chem",
      "author" : [ "M. Mahmoudi", "I. Lynch", "M.R. Ejtehadi", "M.P. Monopoli", "F.B. Bombelli", "S. Laurent" ],
      "venue" : "Rev. 111 ",
      "citeRegEx" : "6",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Nat",
      "author" : [ "S. Tenzer", "D. Docter", "J. Kuharev", "A. Musyanovych", "V. Fetz", "R. Hecht", "F. Schlenk", "D. Fischer", "K. Kiouptsi", "C. Reinhardt" ],
      "venue" : "Nanotechnol. 8 ",
      "citeRegEx" : "7",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Nat",
      "author" : [ "A.E. Nel", "L. Mädler", "D. Velegol", "T. Xia", "E.M. Hoek", "P. Somasundaran", "F. Klaessig", "V. Castranova", "M. Thompson" ],
      "venue" : "Mater. 8 ",
      "citeRegEx" : "8",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Chem",
      "author" : [ "C.D. Walkey", "J.B. Olsen", "H. Guo", "A. Emili", "W.C. Chan", "J. Am" ],
      "venue" : "Soc. 134 ",
      "citeRegEx" : "9",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Chem",
      "author" : [ "J. Lazarovits", "Y.Y. Chen", "E.A. Sykes", "W.C.W. Chan" ],
      "venue" : "Commun. 51 ",
      "citeRegEx" : "10",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Adv",
      "author" : [ "C.Y. Tay", "M.I. Setyawati", "J. Xie", "W.J. Parak", "D.T. Leong" ],
      "venue" : "Funct. Mater. 24 ",
      "citeRegEx" : "11",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Engineering the Nanoparticle-Protein Interface for Cancer Therapeutics",
      "author" : [ "A.A. Saie", "M. Ray", "M. Mahmoudi", "V.M. Rotello" ],
      "venue" : "Nanotechnology-Based Precision Tools for the Detection and Treatment of Cancer, Springer International Publishing",
      "citeRegEx" : "12",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Int",
      "author" : [ "S. Zanganeh", "R. Spitler", "M. Erfanzadeh", "A.M. Alkilany", "M. Mahmoudi" ],
      "venue" : "J. Biochem. Cell Biol. 75 ",
      "citeRegEx" : "13",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Chem",
      "author" : [ "M.I. Setyawati", "C.Y. Tay", "D. Docter", "R.H. Stauber", "D.T. Leong" ],
      "venue" : "Soc. Rev. 44 ",
      "citeRegEx" : "14",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Nanomed",
      "author" : [ "G. Caracciolo" ],
      "venue" : "Nanotech. Biol. Med. 11 ",
      "citeRegEx" : "15",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "M",
      "author" : [ "M. Azhdarzadeh", "A.A. Saei", "S. Sharifi", "M.J. Hajipour", "A.M. Alkilany", "M. Sharifzadeh", "F. Ramazani", "S. Laurent", "A. Mashaghi" ],
      "venue" : "Mahmoudi, Nanomedicine 10 ",
      "citeRegEx" : "16",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Nanomed",
      "author" : [ "L. Bregoli", "D. Movia", "J.D. Gavigan-Imedio", "J. Lysaght", "J. Reynolds", "A. Prina-Mello" ],
      "venue" : "Nanotechnol. Biol. Med. 12 ",
      "citeRegEx" : "17",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "E",
      "author" : [ "C. Corbo", "R. Molinaro", "A. Parodi", "N.E.T. Furman", "F. Salvatore" ],
      "venue" : "Tasciotti, Nanomedicine 11 ",
      "citeRegEx" : "18",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Angew",
      "author" : [ "S. Schöttler", "K. Landfester", "V. Mailänder" ],
      "venue" : "Chem. Int. Ed. 55 ",
      "citeRegEx" : "19",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Trends Biotechnol",
      "author" : [ "G. Caracciolo", "O.C. Farokhzad", "M. Mahmoudi" ],
      "venue" : "",
      "citeRegEx" : "20",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Sci",
      "author" : [ "M.A. Miller", "S. Gadde", "C. Pfirschke", "C. Engblom", "M.M. Sprachman", "R.H. Kohler", "K.S. Yang", "A.M. Laughney", "G. Wojtkiewicz", "N. Kamaly" ],
      "venue" : "Transl. Med. 7 ",
      "citeRegEx" : "21",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Biomater",
      "author" : [ "M.J. Hajipour", "S. Laurent", "A. Aghaie", "F. Rezaee", "M. Mahmoudi" ],
      "venue" : "Sci. 2 ",
      "citeRegEx" : "22",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "A",
      "author" : [ "P.M. Kelly", "C. Åberg", "E. Polo" ],
      "venue" : "O’Connell, J. Cookman, J. Fallon, Ž. Krpetić, K.A. Dawson, Nat. Nanotechnol. 10 ",
      "citeRegEx" : "23",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "A",
      "author" : [ "A. Albanese", "C.D. Walkey", "J.B. Olsen", "H. Guo" ],
      "venue" : "Emili, W.C.W. Chan, ACS Nano 8 ",
      "citeRegEx" : "24",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "M",
      "author" : [ "K. Saha", "M. Rahimi", "M. Yazdani", "S.T. Kim", "D.F. Moyano", "S. Hou", "R. Das", "R. Mout", "F. Rezaee" ],
      "venue" : "Mahmoudi, V.M. Rotello, ACS Nano 10 ",
      "citeRegEx" : "25",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "SPIE BiOS",
      "author" : [ "M. Rahman", "M. Mahmoudi" ],
      "venue" : "International Society for Optics and Photonics",
      "citeRegEx" : "26",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Bioconjug",
      "author" : [ "F. Sonvico", "S. Mornet", "S. Vasseur", "C. Dubernet", "D. Jaillard", "J. Degrouard", "J. Hoebeke", "E. Duguet", "P. Colombo", "P. Couvreur" ],
      "venue" : "Chem. 16 ",
      "citeRegEx" : "27",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Contrast Media Mol",
      "author" : [ "S. Shanehsazzadeh", "C. Gruettner", "A. Lahooti", "M. Mahmoudi", "B.J. Allen", "M. Ghavami", "F.J. Daha", "M.A. Oghabian" ],
      "venue" : "Imaging 10 (2015) 225–236. Please cite this article in press as: M. Mahmoudi, et al., Emerging unde Today ",
      "citeRegEx" : "28",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Int",
      "author" : [ "S. Laurent", "M. Mahmoudi" ],
      "venue" : "J. Mol. Epidemiol. Genet. 2 ",
      "citeRegEx" : "30",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Nat",
      "author" : [ "A. Salvati", "A.S. Pitek", "M.P. Monopoli", "K. Prapainop", "F.B. Bombelli", "D.R. Hristov", "P.M. Kelly", "C. Åberg", "E. Mahon", "K.A. Dawson" ],
      "venue" : "Nanotechnol. 8 (2013) 137–143.  PRESS day xxx ",
      "citeRegEx" : "31",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Chem",
      "author" : [ "V. Mirshafiee", "M. Mahmoudi", "K. Lou", "J. Cheng", "M.L. Kraft" ],
      "venue" : "Commun. 49 ",
      "citeRegEx" : "32",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Nat",
      "author" : [ "K. Strebhardt", "A. Ullrich" ],
      "venue" : "Rev. Cancer 8 ",
      "citeRegEx" : "33",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Acc",
      "author" : [ "J. Shi", "Z. Xiao", "N. Kamaly", "O.C. Farokhzad" ],
      "venue" : "Chem. Res. ",
      "citeRegEx" : "34",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Nat",
      "author" : [ "R.S. Zolot", "S. Basu", "R.P. Million" ],
      "venue" : "Rev. Drug Discov. 12 ",
      "citeRegEx" : "35",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Nanomed",
      "author" : [ "Z. Bakhtiary", "A.A. Saei", "M.J. Hajipour", "M. Raoufi", "O. Vermesh", "M. Mahmoudi" ],
      "venue" : "Nanotech. Biol. Med. 12 ",
      "citeRegEx" : "36",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Proc",
      "author" : [ "H. Chen", "S. Kim", "L. Li", "S. Wang", "K. Park", "J.-X. Cheng" ],
      "venue" : "Natl. Acad. Sci. U. S. A. 105 ",
      "citeRegEx" : "37",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "K",
      "author" : [ "H. Chen", "S. Kim", "W. He", "H. Wang", "P.S. Low" ],
      "venue" : "Park, J.-X. Cheng, Langmuir 24 ",
      "citeRegEx" : "38",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "H",
      "author" : [ "A. Cifuentes-Rius" ],
      "venue" : "de Puig, J.C.Y. Kah, S. Borros, K. Hamad-Schifferli, ACS Nano 7 ",
      "citeRegEx" : "39",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Colloids Surf",
      "author" : [ "S. Behzadi", "V. Serpooshan", "R. Sakhtianchi", "B. Müller", "K. Landfester", "D. Crespy", "M. Mahmoudi" ],
      "venue" : "B 123 ",
      "citeRegEx" : "40",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Chem",
      "author" : [ "R. Mout", "D.F. Moyano", "S. Rana", "V.M. Rotello" ],
      "venue" : "Soc. Rev. 41 ",
      "citeRegEx" : "41",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "M",
      "author" : [ "V. Mirshafiee", "R. Kim", "S. Park" ],
      "venue" : "Mahmoudi, M.L. Kraft, Biomaterials 75 ",
      "citeRegEx" : "42",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Adv",
      "author" : [ "C.S. Kim", "N.D. Le", "Y. Xing", "B. Yan", "G.Y. Tonga", "C. Kim", "R.W. Vachet", "V.M. Rotello" ],
      "venue" : "Healthc. Mater. 3 ",
      "citeRegEx" : "44",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "B",
      "author" : [ "Y. Jiang", "S. Huo", "T. Mizuhara", "R. Das", "Y.-W. Lee", "S. Hou", "D.F. Moyano" ],
      "venue" : "Duncan, X.-J. Liang, V.M. Rotello, ACS Nano 9 ",
      "citeRegEx" : "45",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Mater",
      "author" : [ "C.-F. Wang", "E.M. Mäkilä", "C. Bonduelle", "J. Rytkönen", "J. Raula", "S. Almeida", "A. Närvänen", "J.J. Salonen", "S. Lecommandoux", "J.T. Hirvonen", "H.A. Santos", "ACS Appl" ],
      "venue" : "Interfaces 7 ",
      "citeRegEx" : "46",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Chem",
      "author" : [ "L.A. Trouw", "A.A. Bengtsson", "K.A. Gelderman", "B. Dahlbäck", "G. Sturfelt", "A.M. Blom", "J. Biol" ],
      "venue" : "282 ",
      "citeRegEx" : "47",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "J",
      "author" : [ "J.H. Webb", "A.M. Blom", "B. Dahlbäck" ],
      "venue" : "Immunol. 169 ",
      "citeRegEx" : "48",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "Nat",
      "author" : [ "S. Schöttler", "G. Becker", "S. Winzen", "T. Steinbach", "K. Mohr", "K. Landfester", "V. Mailänder", "F.R. Wurm" ],
      "venue" : "Nanotechnol. 11 ",
      "citeRegEx" : "49",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Nat",
      "author" : [ "M.A. Miller", "Y.-R. Zheng", "S. Gadde", "C. Pfirschke", "H. Zope", "C. Engblom", "R.H. Kohler", "Y. Iwamoto", "K.S. Yang", "B. Askevold", "N. Kolishetti", "M. Pittet", "S.J. Lippard", "O.C. Farokhzad", "R. Weissleder" ],
      "venue" : "Commun. 6 ",
      "citeRegEx" : "50",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "P",
      "author" : [ "C. Von Mering", "R. Krause", "B. Snel", "M. Cornell", "S.G. Oliver", "S. Fields" ],
      "venue" : "Bork, Nature 417 ",
      "citeRegEx" : "51",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "J",
      "author" : [ "J. Kreuter", "T. Hekmatara", "S. Dreis", "T. Vogel", "S. Gelperina", "K. Langer" ],
      "venue" : "Control. Release 118 ",
      "citeRegEx" : "52",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Med",
      "author" : [ "L. Allen", "A. Aderem", "J. Exp" ],
      "venue" : "184 ",
      "citeRegEx" : "53",
      "shortCiteRegEx" : null,
      "year" : 1996
    }, {
      "title" : "R",
      "author" : [ "P. Selvaraj", "W.F. Rosse" ],
      "venue" : "Silber, Nature 333 ",
      "citeRegEx" : "54",
      "shortCiteRegEx" : null,
      "year" : 1988
    }, {
      "title" : "Int",
      "author" : [ "V. Mirshafiee", "R. Kim", "M. Mahmoudi", "M.L. Kraft" ],
      "venue" : "J. Biochem. Cell Biol. 75 ",
      "citeRegEx" : "55",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "A",
      "author" : [ "G. Caracciolo", "S. Palchetti", "V. Colapicchioni", "L. Digiacomo", "D. Pozzi", "A.L. Capriotti", "G. La Barbera" ],
      "venue" : "Laganà, Langmuir 31 ",
      "citeRegEx" : "56",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "T",
      "author" : [ "Y. Cheng", "O. Zak", "P. Aisen", "S.C. Harrison" ],
      "venue" : "Walz, Cell 116 ",
      "citeRegEx" : "57",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "Recognit",
      "author" : [ "A.B. Mason", "S.L. Byrne", "S.J. Everse", "S.E. Roberts", "N.D. Chasteen", "V.C. Smith", "R.T. MacGillivray", "B. Kandemir", "F. Bou-Abdallah", "J. Mol" ],
      "venue" : "22 ",
      "citeRegEx" : "58",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Chem",
      "author" : [ "R. Wang", "H. Kreuzer", "M. Grunze", "J. Phys" ],
      "venue" : "B 101 ",
      "citeRegEx" : "59",
      "shortCiteRegEx" : null,
      "year" : 1997
    }, {
      "title" : "M",
      "author" : [ "H.R. Kim", "K. Andrieux", "C. Delomenie", "H. Chacun", "M. Appel", "D. Desmaële", "F. Taran", "D. Georgin", "P. Couvreur" ],
      "venue" : "Taverna, Electrophoresis 28 ",
      "citeRegEx" : "60",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Nano Lett",
      "author" : [ "J.L. Perry", "K.G. Reuter", "M.P. Kai", "K.P. Herlihy", "S.W. Jones", "J.C. Luft", "M. Napier", "J.E. Bear", "J.M. DeSimone" ],
      "venue" : "12 ",
      "citeRegEx" : "61",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Colloids Surf",
      "author" : [ "R. Gref", "M. Lück", "P. Quellec", "M. Marchand", "E. Dellacherie", "S. Harnisch", "T. Blunk", "R.H. Müller" ],
      "venue" : "B 18 ",
      "citeRegEx" : "62",
      "shortCiteRegEx" : null,
      "year" : 2000
    }, {
      "title" : "W",
      "author" : [ "K.P. García", "K. Zarschler", "L. Barbaro", "J.A. Barreto" ],
      "venue" : "O’Malley, L. Spiccia, H. Stephan, B. Graham, Small 10 ",
      "citeRegEx" : "63",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "S",
      "author" : [ "G. Jia", "Z. Cao", "H. Xue", "Y. Xu" ],
      "venue" : "Jiang, Langmuir 25 ",
      "citeRegEx" : "64",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "H",
      "author" : [ "F. Aldeek", "M.H. Muhammed", "G. Palui", "N. Zhan" ],
      "venue" : "Mattoussi, ACS Nano 7 ",
      "citeRegEx" : "65",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "P",
      "author" : [ "R.R. Arvizo", "O.R. Miranda", "D.F. Moyano", "C.A. Walden", "K. Giri", "R. Bhattacharya", "J.D. Robertson", "V.M. Rotello", "J.M. Reid" ],
      "venue" : "Mukherjee, PLoS One 6 ",
      "citeRegEx" : "66",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "M",
      "author" : [ "D.F. Moyano", "K. Saha", "G. Prakash", "B. Yan", "H. Kong" ],
      "venue" : "Yazdani, V.M. Rotello, ACS Nano 8 ",
      "citeRegEx" : "67",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Mater",
      "author" : [ "R. Safavi-Sohi", "S. Maghari", "M. Raouf", "S.M. JalaliI", "M.J. Hajipour", "A. Ghassempour", "M. Mahmoudi", "ACS Appl" ],
      "venue" : "Interfaces 8 ",
      "citeRegEx" : "68",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "F",
      "author" : [ "A. Verma" ],
      "venue" : "Stellacci, Small 6 ",
      "citeRegEx" : "69",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Adv",
      "author" : [ "M. De", "P.S. Ghosh", "V.M. Rotello" ],
      "venue" : "Mater. 20 ",
      "citeRegEx" : "70",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Bioconjug",
      "author" : [ "C.M. Goodman", "C.D. McCusker", "T. Yilmaz", "V.M. Rotello" ],
      "venue" : "Chem. 15 ",
      "citeRegEx" : "71",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "Nat",
      "author" : [ "G. Helmlinger", "F. Yuan", "M. Dellian", "R.K. Jain" ],
      "venue" : "Med. 3 ",
      "citeRegEx" : "72",
      "shortCiteRegEx" : null,
      "year" : 1997
    }, {
      "title" : "Nat",
      "author" : [ "R.A. Cardone", "V. Casavola", "S.J. Reshkin" ],
      "venue" : "Rev. Cancer 5 ",
      "citeRegEx" : "73",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Angew",
      "author" : [ "T. Mizuhara", "K. Saha", "D.F. Moyano", "C.S. Kim", "B. Yan", "Y.K. Kim", "V.M. Rotello" ],
      "venue" : "Chem. Int. Ed. 54 ",
      "citeRegEx" : "74",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Chem",
      "author" : [ "P.K. Chakravarty", "E.M. Naylor", "A. Chen", "R.S. Chang", "T.-B. Chen", "K.A. Faust", "V.J. Lotti", "S.D. Kivlighn", "R.A. Gable", "J. Med" ],
      "venue" : "37 ",
      "citeRegEx" : "75",
      "shortCiteRegEx" : null,
      "year" : 1994
    }, {
      "title" : "M",
      "author" : [ "M. Mahmoudi", "S.N. Saeedi-Eslami", "M.A. Shokrgozar", "K. Azadmanesh" ],
      "venue" : "rstanding of the protein corona at the nano-bio interfaces, Nano  Hassanlou, H.R. Kalhor, C. Burtea, B. Rothen-Rutishauser, S. Laurent, S. Sheibani, Nanoscale 4 ",
      "citeRegEx" : "76",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "M",
      "author" : [ "M. Mahmoudi", "S. Laurent", "M.A. Shokrgozar" ],
      "venue" : "Hosseinkhani, ACS Nano 5 ",
      "citeRegEx" : "77",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "M",
      "author" : [ "S. Laurent", "C. Burtea", "C. Thirifays", "U.O. Häfeli" ],
      "venue" : "Mahmoudi, PLoS One 7 ",
      "citeRegEx" : "78",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Adv",
      "author" : [ "H. Kang", "J. Gravier", "K. Bao", "H. Wada", "J.H. Lee", "Y. Baek", "G. El Fakhri", "S. Gioux", "B.P. Rubin", "J.L. Coll" ],
      "venue" : "Mater. 28 ",
      "citeRegEx" : "79",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Eur",
      "author" : [ "S. Béni", "Z. Szakács", "O. Csernák", "L. Barcza", "B. Noszál" ],
      "venue" : "J. Pharm. Sci. 30 ",
      "citeRegEx" : "80",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "J",
      "author" : [ "S. Laurent", "C. Burtea", "C. Thirifays", "F. Rezaee", "M. Mahmoudi" ],
      "venue" : "Colloid Interface Sci. 392 ",
      "citeRegEx" : "81",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Chem",
      "author" : [ "H.Y. Mao", "S. Laurent", "W. Chen", "O. Akhavan", "M. Imani", "A.A. Ashkarran", "M. Mahmoudi" ],
      "venue" : "Rev. 113 ",
      "citeRegEx" : "82",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "V",
      "author" : [ "S. Schöttler", "K. Klein", "K. Landfester" ],
      "venue" : "Mailänder, Nanoscale 8 ",
      "citeRegEx" : "83",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "M",
      "author" : [ "L. Kennedy", "T.D. Mehl", "E. Elder" ],
      "venue" : "Varghese, T.J. Merimee, Diabetes 31 ",
      "citeRegEx" : "84",
      "shortCiteRegEx" : null,
      "year" : 1982
    }, {
      "title" : "F",
      "author" : [ "G. Engström", "P. Lind", "B. Hedblad", "L. Stavenow", "L. Janzon" ],
      "venue" : "Lindgärde, Circulation 105 ",
      "citeRegEx" : "85",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "D",
      "author" : [ "S. Acharya" ],
      "venue" : "Dimichele, Haemophilia 14 ",
      "citeRegEx" : "87",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "H",
      "author" : [ "K.S. Kelly-Spratt", "S.J. Pitteri", "K.E. Gurley", "D. Liggitt", "A. Chin", "J. Kennedy", "C.-H. Wong", "Q. Zhang", "T.B. Buson" ],
      "venue" : "Wang, PLoS One 6 ",
      "citeRegEx" : "88",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Pathol",
      "author" : [ "D. Brown", "J. Clin" ],
      "venue" : "55 ",
      "citeRegEx" : "89",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "Nat",
      "author" : [ "K. Blennow", "H. Hampel", "M. Weiner", "H. Zetterberg" ],
      "venue" : "Rev. Neurol. 6 ",
      "citeRegEx" : "90",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "FASEB J",
      "author" : [ "O.M. El-Agnaf", "S.A. Salem", "K.E. Paleologou", "M.D. Curran", "M.J. Gibson", "M.G. Schlossmacher", "D. Allsop" ],
      "venue" : "20 ",
      "citeRegEx" : "92",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Chin",
      "author" : [ "J. Wei", "W. Gao", "C.-J. Zhu", "Y.-Q. Liu", "Z. Mei", "T. Cheng", "Y.-Q. Shu" ],
      "venue" : "J. Cancer 30 ",
      "citeRegEx" : "94",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Ann",
      "author" : [ "H.B. Salt" ],
      "venue" : "Rheum. Dis. 10 ",
      "citeRegEx" : "95",
      "shortCiteRegEx" : null,
      "year" : 1951
    }, {
      "title" : "Cancer Chemother",
      "author" : [ "N.M. La-Beck", "B.A. Zamboni", "A. Gabizon", "H. Schmeeda", "M. Amantea", "P.A. Gehrig", "W.C. Zamboni" ],
      "venue" : "Pharmacol. 69 ",
      "citeRegEx" : "96",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Colloids Surf",
      "author" : [ "G. Caracciolo", "D. Caputo", "D. Pozzi", "V. Colapicchioni", "R. Coppola" ],
      "venue" : "B 123 ",
      "citeRegEx" : "97",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "M",
      "author" : [ "M.J. Hajipour", "J. Raheb", "O. Akhavan", "S. Arjmand", "O. Mashinchian", "M. Rahman", "M. Abdolahad", "V. Serpooshan", "S. Laurent" ],
      "venue" : "Mahmoudi, Nanoscale 7 ",
      "citeRegEx" : "98",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Chem",
      "author" : [ "S. Palchetti", "D. Pozzi", "M. Mahmoudi", "G. Caracciolo", "J. Mater" ],
      "venue" : "B ",
      "citeRegEx" : "99",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Nanotechnol",
      "author" : [ "J. Brewer", "O. Gurel" ],
      "venue" : "Law Bus. 6 ",
      "citeRegEx" : "100",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Nat",
      "author" : [ "G.P. Chrousos" ],
      "venue" : "Rev. Endocrinol. 5 ",
      "citeRegEx" : "101",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Proc",
      "author" : [ "D. Nedelkov", "U.A. Kiernan", "E.E. Niederkofler", "K.A. Tubbs", "R.W. Nelson" ],
      "venue" : "Natl. Acad. Sci. U. S. A. 102 ",
      "citeRegEx" : "102",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Mol",
      "author" : [ "N.L. Anderson", "N.G. Anderson" ],
      "venue" : "Cell. Proteom. 1 ",
      "citeRegEx" : "103",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "Investig",
      "author" : [ "Z.M. Ruggeri", "T.S. Zimmerman", "J. Clin" ],
      "venue" : "65 ",
      "citeRegEx" : "104",
      "shortCiteRegEx" : null,
      "year" : 1980
    }, {
      "title" : "Int",
      "author" : [ "V. Colapicchioni", "M. Tilio", "L. Digiacomo", "V. Gambini", "S. Palchetti", "C. Marchini", "D. Pozzi", "S. Occhipinti", "A. Amici", "G. Caracciolo" ],
      "venue" : "J. Biochem. Cell Biol. 75 ",
      "citeRegEx" : "105",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Chem",
      "author" : [ "A.M. Alkilany", "N.N. Mahmoud", "F. Hashemi", "M.J. Hajipour", "F. Farvadi", "M. Mahmoudi" ],
      "venue" : "Res. Toxicol. 29 ",
      "citeRegEx" : "106",
      "shortCiteRegEx" : null,
      "year" : 2016
    } ],
    "referenceMentions" : [ {
      "referenceID" : 5,
      "context" : "Once in the body, the surface of NPs is rapidly covered by proteins to form a dynamic corona (the so-called “soft” corona) [6]; after a few minutes, NPs become surrounded by a long-",
      "startOffset" : 123,
      "endOffset" : 126
    }, {
      "referenceID" : 2,
      "context" : "rstanding of the protein corona at the nano-bio interfaces, Nano lived (“hard”) corona layer, which remains strongly adsorbed to their surfaces [3,7].",
      "startOffset" : 144,
      "endOffset" : 149
    }, {
      "referenceID" : 6,
      "context" : "rstanding of the protein corona at the nano-bio interfaces, Nano lived (“hard”) corona layer, which remains strongly adsorbed to their surfaces [3,7].",
      "startOffset" : 144,
      "endOffset" : 149
    }, {
      "referenceID" : 8,
      "context" : "The relative importance of each of these forces depends on arious parameters, including the size and the chemical properies of the nanoparticle surface [9].",
      "startOffset" : 152,
      "endOffset" : 155
    }, {
      "referenceID" : 9,
      "context" : "When weak forces ring these apolar regions in the vicinity of hydrophobic surfaces, he protein conformation can change and form strong interactions ith the nanoparticle [10].",
      "startOffset" : 169,
      "endOffset" : 173
    }, {
      "referenceID" : 11,
      "context" : "005 ow the formation of the protein corona affects the hypothetic therpeutic efficacy of NPs and can induce unwanted mistargeting and ide effects [12,13].",
      "startOffset" : 146,
      "endOffset" : 153
    }, {
      "referenceID" : 12,
      "context" : "005 ow the formation of the protein corona affects the hypothetic therpeutic efficacy of NPs and can induce unwanted mistargeting and ide effects [12,13].",
      "startOffset" : 146,
      "endOffset" : 153
    }, {
      "referenceID" : 27,
      "context" : "However, in vivo targeting efficacy was much poorer [28,29].",
      "startOffset" : 52,
      "endOffset" : 59
    }, {
      "referenceID" : 28,
      "context" : ", it may limit the accessibility of the targeting ligands to cell receptors [30].",
      "startOffset" : 76,
      "endOffset" : 80
    }, {
      "referenceID" : 29,
      "context" : "In 2013, further experiments revealed that the protein corona can significantly cover the targeting ligand at the surface of NPs and cause mistargeting [31,32].",
      "startOffset" : 152,
      "endOffset" : 159
    }, {
      "referenceID" : 30,
      "context" : "In 2013, further experiments revealed that the protein corona can significantly cover the targeting ligand at the surface of NPs and cause mistargeting [31,32].",
      "startOffset" : 152,
      "endOffset" : 159
    }, {
      "referenceID" : 30,
      "context" : "[32] used copperfree click reaction between NPs and silicon substrates (Fig.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 38,
      "context" : "ource: Printed with permission from Elsevier publishing group [40].",
      "startOffset" : 62,
      "endOffset" : 66
    }, {
      "referenceID" : 31,
      "context" : "A “magic bullet” to deliver drugs selectively to diseased cells as proposed more than 100 years ago [33].",
      "startOffset" : 100,
      "endOffset" : 104
    }, {
      "referenceID" : 35,
      "context" : "DiIC18(3) and DiOC18(3), a FRET pair, as loaded into the monomethoxy poly(ethylene glycol)-blockoly(D,L-lactic acid) micelles [37].",
      "startOffset" : 126,
      "endOffset" : 130
    }, {
      "referenceID" : 36,
      "context" : "The same authors later demontrated that FRET efficiency was significantly diminished within 5 min after intravenous injection when the same FRET pair in oly(ethylene glycol)-poly(d,l-lactic acid) (PEG-PDLLA) micelles ere used [38], suggesting that DiIC18 and DiOC18 rapidly escaped",
      "startOffset" : 226,
      "endOffset" : 230
    }, {
      "referenceID" : 37,
      "context" : "[39] revealed that the protein corona can substantially change the release profile of the DNA payloads of various nanoparticles including gold nanorods, nanobones, and carbon nanotubes.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 38,
      "context" : "[40] probed the effect of protein corona on release profiles of various nanocarriers including polyethyleneglycol-co-fumarate (PEGF)-coated superparamagnetic iron oxide nanoparticles (SPIONs), poly(methyl methacrylate) polymeric nanocapsules, and commercialized Abraxane® nanocarriers (i.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 24,
      "context" : "Source: Printed with permission from American Chemical Society publishing group [25].",
      "startOffset" : 80,
      "endOffset" : 84
    }, {
      "referenceID" : 40,
      "context" : "ource: Printed with permission from Elsevier publishing group [42].",
      "startOffset" : 62,
      "endOffset" : 66
    }, {
      "referenceID" : 39,
      "context" : "One is controlling the surface funcionality [41] of NPs and the other is pre-coating the surface of NPs ith specific proteins [42] to recruit similar proteins from plasma ainly via protein–protein interactions.",
      "startOffset" : 44,
      "endOffset" : 48
    }, {
      "referenceID" : 40,
      "context" : "One is controlling the surface funcionality [41] of NPs and the other is pre-coating the surface of NPs ith specific proteins [42] to recruit similar proteins from plasma ainly via protein–protein interactions.",
      "startOffset" : 126,
      "endOffset" : 130
    }, {
      "referenceID" : 43,
      "context" : ", fibinogen and immunoglobulin G) in the protein corona [46].",
      "startOffset" : 56,
      "endOffset" : 60
    }, {
      "referenceID" : 44,
      "context" : "Interestingly, one of the main roles of C4BPA is to label apoptotic/necrotic cells for immune system clearance, which explains why positive r with macrophage uptake was observed for NPs with C4BPA-rich corona composition [47,48].",
      "startOffset" : 221,
      "endOffset" : 228
    }, {
      "referenceID" : 45,
      "context" : "Interestingly, one of the main roles of C4BPA is to label apoptotic/necrotic cells for immune system clearance, which explains why positive r with macrophage uptake was observed for NPs with C4BPA-rich corona composition [47,48].",
      "startOffset" : 221,
      "endOffset" : 228
    }, {
      "referenceID" : 46,
      "context" : "[49] demonstrated that a substantial proportion of clustrin protein in the corona composition can significantly reduce a nanoparticle’s uptake by macrophages.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 47,
      "context" : "We have recently shown that tumor-associated macrophages play a critical role in the efficacy of NPs by acting as a slow-release reservoir of payload drugs into the tumor microenvironment [50].",
      "startOffset" : 188,
      "endOffset" : 192
    }, {
      "referenceID" : 48,
      "context" : "Another method of recruiting targeting proteins into the protein corona is to pre-coat NPs with specific proteins to attract desired proteins for the corona, mainly through protein–protein interactions [51].",
      "startOffset" : 202,
      "endOffset" : 206
    }, {
      "referenceID" : 49,
      "context" : ", using ApoA-i and ApoB-100 to cross the blood-brain barrier and target brain tissue [52]), the role of ultimate in vivo identity of NPs in targeting remains unknown.",
      "startOffset" : 85,
      "endOffset" : 89
    }, {
      "referenceID" : 40,
      "context" : "To utilize the power of protein–protein interactions to control the ultimate biological identity of NPs, Mirshafiee and co-workers [42] used a pre-coating strategy to direct the formation of a protein corona that is targeted by",
      "startOffset" : 131,
      "endOffset" : 135
    }, {
      "referenceID" : 40,
      "context" : "ource: Printed with permission from Elsevier publishing group [42].",
      "startOffset" : 62,
      "endOffset" : 66
    }, {
      "referenceID" : 53,
      "context" : "Source: Printed with permission from American Chemical Society publishing group [56].",
      "startOffset" : 80,
      "endOffset" : 84
    }, {
      "referenceID" : 22,
      "context" : "ource: Printed with permission from Nature publishing group [23].",
      "startOffset" : 60,
      "endOffset" : 64
    }, {
      "referenceID" : 50,
      "context" : ", natural killer cells, neutrophils, uman platelets, and macrophages [53,54]).",
      "startOffset" : 69,
      "endOffset" : 76
    }, {
      "referenceID" : 51,
      "context" : ", natural killer cells, neutrophils, uman platelets, and macrophages [53,54]).",
      "startOffset" : 69,
      "endOffset" : 76
    }, {
      "referenceID" : 53,
      "context" : "[56] also demonstrated hat particles whose corona composition was highly enriched in psonins could not bind to macrophage receptors and elicit phagoytosis, mainly due to the unfolding or unavailability of opsonin roteins in the outer corona layer (see Fig.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 22,
      "context" : "In a quite interesting study, Kelly nd co-workers [23] performed epitope mapping on transferrinoated polystyrene NPs 220 nm in size.",
      "startOffset" : 50,
      "endOffset" : 54
    }, {
      "referenceID" : 54,
      "context" : "005 nd a immunogold-labeled polyclonal antibody (pTf) to recogize multiple epitopes simultaneously [57,58].",
      "startOffset" : 99,
      "endOffset" : 106
    }, {
      "referenceID" : 55,
      "context" : "005 nd a immunogold-labeled polyclonal antibody (pTf) to recogize multiple epitopes simultaneously [57,58].",
      "startOffset" : 99,
      "endOffset" : 106
    }, {
      "referenceID" : 56,
      "context" : "One of the early materials proposed for preventing the formaion of the corona was non-charged poly(ethylene glycols) (PEGs), hich have good resistance against non-specific adsorption mainly ecause of their hydrogen bonding with water [59].",
      "startOffset" : 234,
      "endOffset" : 238
    }, {
      "referenceID" : 60,
      "context" : "As PEG clearly could not satisfy the urgent need for fabricaion of corona-free NPs, researchers looking for another candidate aterial decided to pursue the promise of zwitterionic coatings in nhibiting corona formation [63,64].",
      "startOffset" : 219,
      "endOffset" : 226
    }, {
      "referenceID" : 61,
      "context" : "As PEG clearly could not satisfy the urgent need for fabricaion of corona-free NPs, researchers looking for another candidate aterial decided to pursue the promise of zwitterionic coatings in nhibiting corona formation [63,64].",
      "startOffset" : 219,
      "endOffset" : 226
    }, {
      "referenceID" : 62,
      "context" : "terionic coatings demonstrated that they offered an alternative to increase NPs’ biocompatibility and blood circulation time [65,66].",
      "startOffset" : 125,
      "endOffset" : 132
    }, {
      "referenceID" : 63,
      "context" : "terionic coatings demonstrated that they offered an alternative to increase NPs’ biocompatibility and blood circulation time [65,66].",
      "startOffset" : 125,
      "endOffset" : 132
    }, {
      "referenceID" : 64,
      "context" : "[67] determined that no hard protein corona layer was formed.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 65,
      "context" : "[68] fabricated biotin-cysteine-conjugated silica NPs; biotin was selected as the proper targeting molecule, and cysteine was used as a zwitterionic ligand to inhibit corona formation.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 71,
      "context" : "ource: Printed with permission from Wiley publishing group [74].",
      "startOffset" : 59,
      "endOffset" : 63
    }, {
      "referenceID" : 69,
      "context" : "5) than normal tissue [72,73], evelopment of pH-responsive zwitterionic NPs with the capability o become cationic in the cancer microenvironment is of great interst.",
      "startOffset" : 22,
      "endOffset" : 29
    }, {
      "referenceID" : 70,
      "context" : "5) than normal tissue [72,73], evelopment of pH-responsive zwitterionic NPs with the capability o become cationic in the cancer microenvironment is of great interst.",
      "startOffset" : 22,
      "endOffset" : 29
    }, {
      "referenceID" : 71,
      "context" : "[74] proposed an innovative method to fabricate hese NPs using a zwitterionic alkoxyphenyl acylsulfonamide coat-",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 72,
      "context" : "The acylsulfonamide plays a role similar to that of arboxylic acid groups in response to changes in pH value [75].",
      "startOffset" : 109,
      "endOffset" : 113
    }, {
      "referenceID" : 73,
      "context" : "This is presumably due to the “cell vision” effect [76,77].",
      "startOffset" : 51,
      "endOffset" : 58
    }, {
      "referenceID" : 74,
      "context" : "This is presumably due to the “cell vision” effect [76,77].",
      "startOffset" : 51,
      "endOffset" : 58
    }, {
      "referenceID" : 75,
      "context" : "It is noteworthy that cell vision is a variation of the detoxification strategies that any cell can use in response to toxins, drugs, and NPs [78].",
      "startOffset" : 142,
      "endOffset" : 146
    }, {
      "referenceID" : 76,
      "context" : "[79] developed an innovative zwitterionic nanocarrier for high-yield delivery of anticancer drugs to tumor sites with negligible side effects to normal cells, mainly due to the rapid renal clearance of untargeted nanocar-",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 76,
      "context" : "ource: Printed with permission from Wiley publishing group [79].",
      "startOffset" : 59,
      "endOffset" : 63
    }, {
      "referenceID" : 77,
      "context" : "It is noteworthy that a fluoresent dye (Cy3 N-hydroxysuccinimide Ester)-conjugated imatinib as used in the nanocarrier to both target the tyrosine-kinase nhibitor for treating GIST [80] and track the biodistribution of the anocarriers.",
      "startOffset" : 181,
      "endOffset" : 185
    }, {
      "referenceID" : 69,
      "context" : "Due to the acidic environment of tumor site [72,73], the drug can then be released by forming a stable inclusion complex [79].",
      "startOffset" : 44,
      "endOffset" : 51
    }, {
      "referenceID" : 70,
      "context" : "Due to the acidic environment of tumor site [72,73], the drug can then be released by forming a stable inclusion complex [79].",
      "startOffset" : 44,
      "endOffset" : 51
    }, {
      "referenceID" : 76,
      "context" : "Due to the acidic environment of tumor site [72,73], the drug can then be released by forming a stable inclusion complex [79].",
      "startOffset" : 121,
      "endOffset" : 125
    }, {
      "referenceID" : 78,
      "context" : ", human plasma, human serum, and fetal bovine serum) has a significant effect on the composition of the protein corona [81]; in turn, different corona",
      "startOffset" : 119,
      "endOffset" : 123
    }, {
      "referenceID" : 79,
      "context" : "rstanding of the protein corona at the nano-bio interfaces, Nano compositions cause considerable changes in cellular uptake and intracellular traficking of NPs [82,83].",
      "startOffset" : 160,
      "endOffset" : 167
    }, {
      "referenceID" : 80,
      "context" : "rstanding of the protein corona at the nano-bio interfaces, Nano compositions cause considerable changes in cellular uptake and intracellular traficking of NPs [82,83].",
      "startOffset" : 160,
      "endOffset" : 167
    }, {
      "referenceID" : 76,
      "context" : "c t C u p ource: Printed with permission from Wiley publishing group [79].",
      "startOffset" : 69,
      "endOffset" : 73
    }, {
      "referenceID" : 83,
      "context" : "rstanding of the protein corona at the nano-bio interfaces, Nano hemopexin, apolipoprotein A-IV, complement factor B, and complement factor H [87,95].",
      "startOffset" : 142,
      "endOffset" : 149
    }, {
      "referenceID" : 89,
      "context" : "rstanding of the protein corona at the nano-bio interfaces, Nano hemopexin, apolipoprotein A-IV, complement factor B, and complement factor H [87,95].",
      "startOffset" : 142,
      "endOffset" : 149
    }, {
      "referenceID" : 99,
      "context" : "ource: Printed with permission from Elsevier publishing group [105].",
      "startOffset" : 62,
      "endOffset" : 67
    }, {
      "referenceID" : 13,
      "context" : "It is increasingly being accepted that variation in plasma roteins caused by disease type can significantly change the comosition of the protein corona at the surface of NPs [14,22,97] and onsequently their interactions with biological species [16,98,99].",
      "startOffset" : 174,
      "endOffset" : 184
    }, {
      "referenceID" : 21,
      "context" : "It is increasingly being accepted that variation in plasma roteins caused by disease type can significantly change the comosition of the protein corona at the surface of NPs [14,22,97] and onsequently their interactions with biological species [16,98,99].",
      "startOffset" : 174,
      "endOffset" : 184
    }, {
      "referenceID" : 91,
      "context" : "It is increasingly being accepted that variation in plasma roteins caused by disease type can significantly change the comosition of the protein corona at the surface of NPs [14,22,97] and onsequently their interactions with biological species [16,98,99].",
      "startOffset" : 174,
      "endOffset" : 184
    }, {
      "referenceID" : 15,
      "context" : "It is increasingly being accepted that variation in plasma roteins caused by disease type can significantly change the comosition of the protein corona at the surface of NPs [14,22,97] and onsequently their interactions with biological species [16,98,99].",
      "startOffset" : 244,
      "endOffset" : 254
    }, {
      "referenceID" : 92,
      "context" : "It is increasingly being accepted that variation in plasma roteins caused by disease type can significantly change the comosition of the protein corona at the surface of NPs [14,22,97] and onsequently their interactions with biological species [16,98,99].",
      "startOffset" : 244,
      "endOffset" : 254
    }, {
      "referenceID" : 93,
      "context" : "It is increasingly being accepted that variation in plasma roteins caused by disease type can significantly change the comosition of the protein corona at the surface of NPs [14,22,97] and onsequently their interactions with biological species [16,98,99].",
      "startOffset" : 244,
      "endOffset" : 254
    }, {
      "referenceID" : 25,
      "context" : "For instance, it was demonstrated that silica and polystyrene Ps affect the conformation of fibrinogen protein in the corona prouced by healthy individuals, substantially promoting the body’s elease of inflammatory cytokines [26].",
      "startOffset" : 225,
      "endOffset" : 229
    }, {
      "referenceID" : 99,
      "context" : "[105] showed significant variation mong the protein corona profiles of healthy donors (Fig.",
      "startOffset" : 0,
      "endOffset" : 5
    }, {
      "referenceID" : 100,
      "context" : "This trongly suggests that in order to accelerate the clinical translaion of NPs, researchers in the field should clearly report detailed nformation regarding the human serum/plasma (including type f disease, age, and gender) they use for each study; such precise nformation will minimize misinterpretation of protein corona data or in vivo applications [106].",
      "startOffset" : 354,
      "endOffset" : 359
    } ],
    "year" : 2016,
    "abstractText" : "Upon entering the physiological environment, nanoparticles (NPs) are immediately surrounded by a complex and tightly bound layer of biomolecules, or ‘(hard) protein corona’. The corona controls NP fate in vivo and becomes the interface with cells. One of nanomedicine’s central goals is to make NPs capable of active targeting in both imaging and therapy. If the NP is not designed correctly, the resulting corona vailable online xxx",
    "creator" : "Elsevier"
  }
}